|
e74057db-dd68-4b8a-bcd8-dd7b8ae16889
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
iweumhqz-7385
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
COMMUNITY CARE PROVIDE
|
COMMUNITY CARE PROVIDER - MEDICAL
|
/home/sid/tuning/finetune/backend/output/iweumhqz- /home/sid/tuning/finetune/backend/output/iweumhqz-7385/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Document Description
The provided text is a compi Document Description
The provided text is a compilation of two distinct medical documents. The first document is the front matter of the textbook "Internal Medicine," published by Cambridge University Press in 2007 and edited by Bruce F. Scharschmidt, MD. This section includes the title page, copyright information, a detailed disclaimer regarding medical liability, and a list of the editor and associate editors who are experts from prestigious institutions like Yale, Harvard, and UCSF. It also features a comprehensive Table of Contents that lists hundreds of medical topics ranging from abdominal disorders to neurological conditions. The second document is the VA Form 10-10172 (March 2025), titled "Community Care Provider - Medical / Durable Medical Equipment." This form is an administrative tool used by ordering providers to request authorization for Veterans to receive medical services, home oxygen, or prosthetics from community care providers. It requires detailed clinical information such as diagnosis codes, medication lists, specific equipment measurements, and diabetic risk assessments to justify the medical necessity of the requested items.
Key Points
Part 1: Internal Medicine Textbook
Editorial Team: Led by Bruce F. Scharschmidt, with associate editors covering major specialties (Cardiology, Neurology, Infectious Disease, etc.).
Disclaimer: Emphasizes that medical standards change constantly and clinicians must use independent judgment and verify current drug information.
Reference Nature: Serves as a comprehensive, A-Z handbook (PocketMedicine) covering diseases, syndromes, and conditions.
Institutions: Contributors hail from top-tier schools such as the University of California, Stanford, and Harvard Medical School.
Part 2: VA Request for Service Form (10-10172)
Purpose: Used to request authorization for medical services or DME (Durable Medical Equipment) not originally authorized or needing renewal.
Submission Requirements: Requires the provider's signature, NPI number, and attached medical records (office notes, labs, radiology).
Specific Sections:
Medical: Requires ICD-10 codes and CPT/HCPCS codes.
Oxygen: Requires specific flow rates and saturation levels.
Therapeutic Footwear: Requires a "Risk Score" based on sensory loss, circulation, and deformity.
Urgency: Includes a section to flag if care is needed within 48 hours.
Topics and Headings
Medical Literature & Reference
Internal Medicine Textbook Structure
Expert Affiliations and Academic Credentials
Medical Liability and Disclaimers
Alphabetical Index of Medical Conditions
Veterans Affairs Administration
Community Care Authorization Process
Clinical Documentation Requirements
Medical Coding (ICD-10 and CPT/HCPCS)
Durable Medical Equipment (DME) Protocols
Diabetic Footwear Assessment Criteria
Home Oxygen Therapy Qualification
Questions for Review
Regarding the Textbook: Who is the primary editor of the "Internal Medicine" textbook, and in what year was this specific version published?
Regarding the VA Form: What is the VA form number provided for the "Community Care Provider - Medical" request?
Clinical Criteria: According to the VA form, what specific "Risk Score" must a patient meet to be eligible for therapeutic footwear?
Process: What three specific items (attachments) are required to be submitted along with the VA Request for Service form?
Scope: What is the primary difference in content between the first document (the textbook intro) and the second document (the VA form)?
Easy Explanation
The text you provided is like looking at two different tools a doctor uses.
1. The Textbook (The "Brain")
Imagine a massive encyclopedia specifically for doctors. This is the "Internal Medicine" book. It lists almost every sickness you can think of, from A (Abdominal Aortic Aneurysm) to Z (Zoster). It’s written by super-smart professors from top universities. It’s meant to help a doctor quickly look up how to treat a disease or what symptoms to look for.
2. The VA Form (The "Permission Slip")
Imagine a Veteran needs a medical service or a piece of equipment (like an oxygen tank or special shoes) that the VA hospital can't provide directly. The doctor needs to fill out a permission slip to ask the VA if it's okay to send the Veteran to a private doctor or store. This form (VA Form 10-10172) asks for proof: "Why do they need this?" "What exactly is the medical code?" and "Is it an emergency?" It makes sure the VA pays for it correctly.
Presentation Outline
Slide 1: Introduction
Title: Overview of Medical Documentation Resources
Objective: Understanding the distinction between clinical reference texts and administrative authorization forms.
Slide 2: The "Internal Medicine" Textbook
Source: Cambridge University Press (2007).
Role: A reference guide for diagnosis and management.
Key Feature: Contributions from specialists in every field (Heart, Skin, Brain, etc.).
Usage: Used by clinicians to answer "What is this condition and how do I treat it?"
Slide 3: VA Form 10-10172 – Request for Service
Source: Department of Veterans Affairs (March 2025).
Role: Administrative tool for approval of outside care.
Key Requirement: Justification of "Medical Necessity."
Usage: Used to answer "Can I get approval for this specific treatment or equipment for a Veteran?"
Slide 4: Detailed Breakdown of the VA Form
Section I: Veteran & Provider Info (Names, NPI, Address).
Section II: Type of Care (Medical Services, Home Oxygen, DME).
Clinical Data: Requires Diagnosis (ICD-10) and Procedure (CPT) codes.
Specialized Assessments:
Oxygen: Flow rates and saturation.
Footwear: Risk scores based on neuropathy and circulation.
Slide 5: Summary
Document 1 provides the knowledge to treat patients.
Document 2 provides the process to access resources for patients.
Both are essential for the complete cycle of patient care....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/iweumhqz-7385/data/document.pdf"}...
|
/home/sid/tuning/finetune/backend/output/iweumhqz- /home/sid/tuning/finetune/backend/output/iweumhqz-7385/data/iweumhqz-7385.json...
|
null
|
failed
|
1769633149
|
1769634051
|
NULL
|
/home/sid/tuning/finetune/backend/output/iweumhqz- /home/sid/tuning/finetune/backend/output/iweumhqz-7385/adapter...
|
False
|
Edit
Delete
|
|
4f8bdc68-48a1-4478-8665-fb132371e3bd
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
pvjymjqk-4750
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
breast cancer Chapter
|
breast cancer Chapter_1-Introduction
|
/home/sid/tuning/finetune/backend/output/pvjymjqk- /home/sid/tuning/finetune/backend/output/pvjymjqk-4750/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Paragraph Description
The document &# 1. Complete Paragraph Description
The document "Chapter 1: Introduction" is the opening section of a medical thesis focused on breast cancer screening strategies. It provides a comprehensive overview of breast cancer, defining it as the uncontrolled growth of cells in the breast tissue (specifically the lobules, ducts, or connective tissue) and explaining the progression from non-invasive to invasive stages. The text details the etiology and risk factors, including genetic predispositions (BRCA1/2 mutations) and lifestyle influences, and reviews global epidemiology trends regarding incidence and mortality. A significant portion of the text is dedicated to analyzing screening (secondary prevention), weighing the benefits of early detection and mortality reduction against the harms of false positives, overdiagnosis, and radiation exposure. It further outlines current treatment protocols, international screening guidelines, and introduces the thesis's objective of using simulation modeling (MISCAN-Fadia) to evaluate and improve upon current age-based screening strategies by moving toward risk-based approaches.
2. Key Points, Topics, and Headings
Anatomy & Definition:
Breast Cancer: Uncontrolled cell growth forming a malignant tumor.
Locations: Begins in lobules (milk glands), ducts (tubes), or connective tissue.
Types: In situ (non-invasive, confined) vs. Invasive (spread to healthy tissue).
Staging Systems:
TNM System: Classifies based on Tumor size, Number of lymph Nodes involved, and presence of Metastasis.
SEER System: Localized vs. Regional vs. Distant spread.
Etiology & Risk Factors:
Non-Modifiable: Age (highest incidence 50-74), Genetics (BRCA1/2, SNPs), Family history, Dense breasts.
Modifiable: Postmenopausal obesity, alcohol, physical inactivity, radiation exposure.
Hormonal: Early menarche, late menopause, hormone replacement therapy (HRT).
Epidemiology:
Incidence increases with age.
Mortality has declined due to better screening/treatment.
Incidence dropped in early 2000s after reduced HRT use.
Screening (Secondary Prevention):
Goal: Detect cancer in the "pre-clinical" phase.
Benefits: True positives, early diagnosis leads to better survival and less invasive treatment.
Harms:
False Positives: Unnecessary anxiety and follow-up tests.
Overdiagnosis: Detecting tumors that would never have caused harm.
Radiation: Potential risk from ionizing radiation (mammograms).
Treatment:
Surgery: Lumpectomy (breast-conserving) vs. Mastectomy (removal of breast).
Therapies: Systemic (chemo, hormone, radiation) for spread; Neoadjuvant (before surgery) to shrink tumors.
Guidelines (Who gets screened?):
USPSTF: Age 50-74, every 2 years.
ACS: Choice 40-45, Annual 45-54, Biennial 55-74.
IARC (WHO): Age 50-69.
The Future (Thesis Focus):
Risk-Based Screening: Moving away from "one size fits all" (age only) to tailoring screening based on density, genetics, and family history.
Modeling: Using the MISCAN-Fadia simulation model to predict outcomes of different strategies.
3. Review Questions (Based on the text)
What is the difference between "In situ" and "Invasive" breast cancer?
Answer: "In situ" cancers are non-invasive and confined to the ducts or lobules. "Invasive" cancers have grown into healthy tissues and can spread to other parts of the body.
In the TNM staging system, what do the letters T, N, and M stand for?
Answer: T = Tumor size, N = Number of nearby lymph nodes involved, M = Metastasis (spread to distant parts of the body).
What are two "modifiable" risk factors for breast cancer mentioned in the text?
Answer: Postmenopausal obesity, alcohol consumption, physical inactivity, or exposure to radiation.
Explain the concept of "Overdiagnosis" in the context of breast cancer screening.
Answer: Overdiagnosis occurs when screening detects a tumor that would never have caused symptoms or death in a woman's lifetime, leading to unnecessary treatment.
Why did breast cancer incidence drop in the early 2000s according to the text?
Answer: It dropped because the use of Hormone Replacement Therapy (HRT) was reduced after it was found to increase breast cancer risk.
What is "Neoadjuvant" breast cancer treatment?
Answer: Treatment (like chemo) applied before surgical intervention to stop cancer growth and shrink the tumor size.
Why does the thesis author prefer using "Simulation Models" (like MISCAN-Fadia) alongside Randomized Clinical Trials (RCTs)?
Answer: RCTs are expensive, time-consuming, and ethically difficult to run forever. Models can synthesize data to predict outcomes for multiple strategies and risk groups that haven't been tested in trials yet.
4. Easy Explanation
Think of this document as a "Strategy Guide for Fighting Breast Cancer."
It breaks down the fight into four phases:
Know the Enemy: It explains what cancer is (bad cells growing in ducts/lobules) and how it spreads (staging).
Spot the Risk: It identifies who is most likely to get it. It's mostly about age and genes (BRCA), but also things like weight and alcohol.
The Defense (Screening): This is the biggest part of the text. It discusses using mammograms (X-rays) to find cancer early. It admits this defense isn't perfect—it can scare you with false alarms or find "tumors" that were never actually dangerous (overdiagnosis).
The Counter-Attack (Treatment & Future): If cancer is found, you can cut it out (surgery) or poison it (chemo). The author's main goal is to use computer simulations to figure out a smarter way to defend women—screening only those who actually need it most, rather than everyone of a certain age.
5. Presentation Outline
Slide 1: Introduction to Breast Cancer
Definition: Uncontrolled cell growth.
Anatomy: Lobules, Ducts, Connective tissue.
Invasive vs. Non-invasive.
Slide 2: Staging the Disease
TNM System (Tumor, Nodes, Metastasis).
Why staging matters (Guiding treatment).
Slide 3: Risk Factors
Non-Modifiable: Age, Genetics (BRCA), Family History.
Modifiable: Obesity, Alcohol, Inactivity.
The role of Breast Density.
Slide 4: Epidemiology Trends
Correlation with Age.
Impact of HRT reduction.
Decline in mortality rates.
Slide 5: The Screening Debate (Benefits)
Goal: Early detection (Pre-clinical phase).
Benefit: Mortality reduction (approx. 20-23%).
Less invasive treatment for early stages.
Slide 6: The Harms of Screening
False Positives (Anxiety/Unnecessary tests).
Overdiagnosis (Treating harmless tumors).
Radiation exposure.
Slide 7: Treatment Options
Lumpectomy vs. Mastectomy.
Adjuvant vs. Neoadjuvant therapy.
Slide 8: Current Guidelines
USPSTF (Age 50-74).
American Cancer Society (Age 40+).
IARC (Age 50-69).
Slide 9: The Future of Screening (Thesis Focus)
Moving to "Risk-Based" screening.
Using Simulation Models (MISCAN-Fadia).
Personalizing care to reduce harm.
Slide 10: Conclusion
Summary: Screening saves lives but has costs.
Goal: Optimize the harm-benefit ratio....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/pvjymjqk-4750/data/document.pdf", "num_examples": 52, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/pvjymjqk- /home/sid/tuning/finetune/backend/output/pvjymjqk-4750/data/pvjymjqk-4750.json...
|
null
|
queued
|
1769633378
|
1769636972
|
NULL
|
/home/sid/tuning/finetune/backend/output/pvjymjqk- /home/sid/tuning/finetune/backend/output/pvjymjqk-4750/adapter...
|
False
|
Edit
Delete
|
|
31a8768b-b003-40b3-909e-2f6c78e4dbaa
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
fejmascl-9736
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
An Introduction to Bre
|
An Introduction to Breast cancer.pdf
|
/home/sid/tuning/finetune/backend/output/fejmascl- /home/sid/tuning/finetune/backend/output/fejmascl-9736/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Document Description
The provided text compiles t Document Description
The provided text compiles three distinct types of medical and administrative resources. First, it presents the front matter of the "Internal Medicine" textbook published by Cambridge University Press in 2007, which serves as a comprehensive reference guide listing hundreds of medical topics and includes the credentials of numerous editors from prestigious institutions. Second, it includes the official "Community Care Provider - Medical" and DME request forms (VA Form 10-10172, March 2025), which are administrative tools designed for healthcare providers to request authorization for Veterans to receive medical services, home oxygen, or prosthetics in the community. Third, the text contains the content of a medical presentation titled "An Introduction to Breast Cancer," which provides an educational overview of breast cancer epidemiology, anatomy, risk factors, screening guidelines (including mammography and MRI), and pathology, aimed at medical professionals and students.
Key Points
1. Internal Medicine Textbook
Reference Guide: A 2007 publication serving as a pocket guide for diagnosis and management across all medical specialties.
Contributors: Written and edited by experts from top institutions like UCSF, Harvard, and Yale.
Scope: Alphabetically lists conditions from "Abscesses" to "Zoster."
2. VA Community Care Form (10-10172)
Purpose: An administrative form to authorize care for Veterans outside the VA facility.
Requirements: Demands detailed clinical justification, including ICD-10 diagnosis codes and CPT/HCPCS procedure codes.
Specific Sections: Includes unique criteria for Home Oxygen (flow rates) and Therapeutic Footwear (diabetic risk scores).
3. Breast Cancer Presentation
Epidemiology: Breast cancer is the most common cancer in women, with a lifetime risk of 1 in 8 (12.5%).
Risk Factors: Increasing age is the most significant risk factor; genetics (BRCA1/2) and family history also play a major role.
Screening: Annual mammograms are recommended starting at age 40 for average-risk women; MRI is recommended for high-risk women.
Diagnosis: MRI is more sensitive than mammography, particularly in dense breasts or for detecting contralateral disease.
Topics and Headings
Medical Reference Literature
Textbook Publication and Copyright
Editorial Board and Affiliations
Alphabetical Index of Internal Medicine Conditions
Veterans Health Administration (VHA)
Community Care Authorization Process
Medical Documentation and Coding (ICD-10/CPT)
Durable Medical Equipment (DME) Policies
Diabetic Footwear and Home Oxygen Requirements
Clinical Oncology (Breast Cancer)
Epidemiology and Risk Factors
Breast Anatomy and Pathology (DCIS vs. Invasive)
Screening Guidelines (ACS Recommendations)
Diagnostic Imaging (Mammography vs. MRI)
Hormone Receptor and HER2 Status
Questions for Review
Textbook: Who is the primary editor of the "Internal Medicine" textbook, and what year was it published?
VA Form: What is the specific "Risk Score" required on the VA form for a diabetic patient to qualify for therapeutic footwear?
Breast Cancer: According to the presentation, what is a woman's lifetime risk of developing invasive breast cancer?
Screening: At what age does the American Cancer Society recommend annual mammogram screening begin for women at average risk?
Administration: What specific form number is used to request Durable Medical Equipment (DME) for a Veteran?
Easy Explanation
The text provided is a collection of three different tools used in the medical field:
The Medical Textbook: Think of this as a "Google" for doctors. It’s a big book (from 2007) that lists almost every disease and how to treat it, written by professors from famous universities.
The VA Form: This is a "permission slip" for Veterans. If a Veteran needs medical care or equipment (like oxygen tanks or special shoes) that the VA hospital can't provide, the doctor fills out this form to ask the government for permission and money to get it elsewhere.
The Breast Cancer Presentation: This is like a class lecture. It teaches doctors about breast cancer—how common it is, who is most likely to get it, and the best ways to check for it (like mammograms and MRIs).
Presentation Outline
Slide 1: Overview of Medical Documentation
Introduction to three distinct medical resources.
Purpose: Clinical reference, administrative authorization, and patient education.
Slide 2: The "Internal Medicine" Textbook
Source: Cambridge University Press, 2007.
Content: Comprehensive A-Z list of diseases.
Utility: Quick reference for diagnosis and treatment standards.
Slide 3: VA Community Care Authorization (Form 10-10172)
Function: Securing funding for non-VA care.
Key Elements:
Requires medical codes (ICD-10, CPT).
Specific checks for DME (Oxygen, Footwear).
Attestation of medical necessity.
Slide 4: Breast Cancer - Epidemiology & Risks
Stats: 2nd leading cause of cancer death in women.
Lifetime Risk: 12.5% (1 in 8).
Major Risk: Increasing age (most significant).
Genetics: BRCA1/BRCA2 mutations.
Slide 5: Breast Cancer - Screening & Diagnosis
Standard Care: Mammograms starting at age 40.
High Risk: MRI screening starting at age 30.
Findings: MRI detects occult malignancies (3-5%) that mammograms miss.
Slide 6: Summary
These documents represent the workflow of medicine:
Knowledge: The Textbook.
Process: The VA Form.
Application: The Clinical Presentation....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/fejmascl-9736/data/document.pdf", "num_examples": 26, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/fejmascl- /home/sid/tuning/finetune/backend/output/fejmascl-9736/data/fejmascl-9736.json...
|
null
|
queued
|
1769633407
|
1769634590
|
NULL
|
/home/sid/tuning/finetune/backend/output/fejmascl- /home/sid/tuning/finetune/backend/output/fejmascl-9736/adapter...
|
False
|
Edit
Delete
|
|
71d9e0e9-a85b-417a-ada3-b408f3396112
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
hlfxzkrv-7283
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
breast cancer epidemioloy
|
breast cancer epidemiology.pdf
|
/home/sid/tuning/finetune/backend/output/hlfxzkrv- /home/sid/tuning/finetune/backend/output/hlfxzkrv-7283/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Paragraph Description
The document &# 1. Complete Paragraph Description
The document "Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)" published in the journal Cancers (2022) is a comprehensive review that synthesizes current medical knowledge regarding breast cancer. It begins with an epidemiological overview, establishing breast cancer as the most common malignant tumor in women globally, noting that while incidence is highest in developed nations due to "Western lifestyle" and screening availability, mortality remains disproportionately high in developing nations due to lack of resources. The text provides a detailed analysis of risk factors, categorizing them into hormonal/reproductive (early menarche, HRT), genetic (BRCA mutations), lifestyle (diet, obesity, alcohol), and environmental (radiation). Finally, it reviews the pathology and classification of the disease, detailing the WHO classification system, histological grading (Bloom-Richardson-Scarff), and the TNM staging system, while highlighting the prognostic significance of lymph node involvement and molecular markers (ER, PR, HER2).
2. Key Points, Topics, and Headings
Epidemiology:
Global Burden: Most common malignant tumor in women; 2.089 million new cases in 2018.
Incidence: Highest in industrialized countries (Western lifestyle: poor diet, low activity).
Mortality: Highest in developing countries (lack of screening, late diagnosis, limited treatment).
Screening: Mammography has a sensitivity of 75–95% and specificity of 80–95%.
Risk Factors:
Demographics: 99% occur in women; risk increases with age (rising in under-50s).
Hormonal: Prolonged exposure to estrogen (early menarche <12, late menopause >54). HRT and oral contraceptives increase risk.
Genetic: BRCA1/2 mutations (3-5% of patients); other genes (TP53, PTEN, ATM).
Benign Lesions: Atypical hyperplasia increases risk 4-5 times.
Lifestyle: Alcohol (9% increase per 10g/day), Postmenopausal obesity (adipose tissue produces estrogen), Western diet.
Radiation: Exposure at a young age increases cumulative risk.
Pathology & Classification:
Common Types: NST (No Special Type) – 70-80%; Lobular – 10%.
Grading (Bloom-Richardson-Scarff): Assessed by tubule formation, nuclear pleomorphism, and mitotic figures (Grades 1-3).
Staging (TNM 8th Edition):
T: Tumor size (Tis, T1, T2, T3, T4).
N: Lymph nodes (N0-N3, including micro-metastases).
M: Metastasis (M0, M1).
Molecular Markers: Estrogen Receptors (ER), Progesterone Receptors (PR), HER2 status.
Prognostic Factors:
Most important: Stage and Lymph node status.
Survival: 5-year survival is much lower if lymph nodes are occupied.
3. Review Questions (Based on the text)
According to the review, why is breast cancer incidence higher in developed countries compared to developing countries?
Answer: It is associated with "Western lifestyle" (poor diet, lack of physical activity, stress, nicotinism) and the availability of screening which detects more cases.
What are the two most common histological types of invasive breast cancer mentioned?
Answer: Cancer without a special type (NST) – 70-80%, and Lobular carcinoma – 10%.
How does obesity affect breast cancer risk differently in premenopausal versus postmenopausal women?
Answer: In premenopausal women, obesity may reduce the risk of hormone-dependent cancer, whereas in postmenopausal women, it increases the risk significantly (adipose tissue is the main source of estrogen).
In the TNM staging system, what does "N1mi" indicate?
Answer: It indicates micro-metastases (>0.2 mm or >200 cells) detected in 1–3 regional lymph nodes.
What is the "cumulative risk" of developing breast cancer by age 70 for carriers of BRCA1/BRCA2 gene mutations?
Answer: It is more than 60%, with a lifetime risk ranging from 41–90%.
What are the three features assessed to determine the histological grade (malignancy) of a breast tumor?
Answer: Formation of coils and glands, nuclear pleomorphism (degree of nuclei atypia), and the number of figures of cancer cell division (mitotic count).
4. Easy Explanation
Think of this document as a "Research Summary on Breast Cancer" for doctors. It gathers all the facts scientists currently know to answer three big questions: Who gets it? Why do they get it? And what does it look like?
Who gets it? Mostly older women, but increasingly younger women. It's more common in rich countries (due to diet/lifestyle) but deadlier in poor countries (due to lack of hospitals/screening).
Why?
Genes: If you have BRCA mutations, your risk is huge.
Hormones: The longer your body is exposed to estrogen (early periods, late menopause, hormone pills), the higher the risk.
Weight: Being very overweight after menopause is dangerous because fat tissue creates estrogen.
What does it look like? Doctors look at the cancer cells under a microscope to "grade" them (how weird do the nuclei look? are they dividing fast?) and "stage" them (how big is it? has it spread to lymph nodes?).
The text confirms that while we have good treatments, understanding these risk factors and biological details is crucial for finding a cure.
5. Presentation Outline
Slide 1: Global Epidemiology of Breast Cancer
Most common malignant tumor in women.
Incidence vs. Mortality (Developed vs. Developing nations).
The role of "Western Lifestyle" and Screening.
Slide 2: Non-Modifiable Risk Factors
Sex (99% women) and Age (Risk increases with age).
Genetics: BRCA1/2 and other gene mutations.
Family History and Benign Lesions (Atypical Hyperplasia).
Slide 3: Modifiable & Lifestyle Risk Factors
Hormonal Factors: HRT, Oral Contraceptives.
Obesity (Postmenopausal risk vs. Premenopausal protection).
Diet (Western vs. Healthy) and Alcohol Consumption.
Radiation exposure.
Slide 4: Pathology & Classification
WHO Classification.
Common Subtypes: NST (70-80%) and Lobular (10%).
Histological Grading (Bloom-Richardson-Scarff): Tubules, Nuclei, Mitosis.
Slide 5: Staging the Disease (TNM System)
T: Primary Tumor size (T1-T4).
N: Regional Lymph Nodes (N0-N3) – Prognostic importance.
M: Distant Metastasis.
Slide 6: Molecular Markers & Prognosis
Importance of ER, PR, and HER2 status.
5-Year Survival statistics based on stage.
The link between staging and treatment success.
Slide 7: Conclusion
Summary of multifactorial etiology.
The importance of early detection and understanding risk.
Future directions in treatment....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/hlfxzkrv-7283/data/document.pdf", "num_examples": 58, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/hlfxzkrv- /home/sid/tuning/finetune/backend/output/hlfxzkrv-7283/data/hlfxzkrv-7283.json...
|
null
|
queued
|
1769633562
|
1769644957
|
NULL
|
/home/sid/tuning/finetune/backend/output/hlfxzkrv- /home/sid/tuning/finetune/backend/output/hlfxzkrv-7283/adapter...
|
False
|
Edit
Delete
|
|
79d1071f-77bf-46d0-a1d6-e4b138a30e42
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
nejpulrp-2874
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Guidelines for management
|
39 Guidelines for management of breast cancer
|
/home/sid/tuning/finetune/backend/output/nejpulrp- /home/sid/tuning/finetune/backend/output/nejpulrp-2874/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Document Description
The provided text compiles f Document Description
The provided text compiles four distinct medical resources designed for education, reference, and administration. The first section is the front matter of the "Internal Medicine" textbook published by Cambridge University Press in 2007, featuring a comprehensive table of contents that lists hundreds of medical conditions and the affiliations of its editors from prestigious institutions. The second section presents the "Community Care Provider - Medical" and DME request forms (VA Form 10-10172, March 2025), which are administrative documents requiring clinicians to justify medical necessity, provide diagnosis codes, and assess diabetic risk scores to authorize community care for Veterans. The third section is a medical presentation titled "An Introduction to Breast Cancer" by Dr. Katherine S. Tzou of the Mayo Clinic, which educates readers on breast cancer epidemiology, anatomy, risk factors, and screening protocols, specifically comparing mammography and MRI. Finally, the fourth section contains the "Guidelines for Management of Breast Cancer" published by the WHO Regional Office for the Eastern Mediterranean in 2006, offering clinical protocols for diagnosis, staging, systemic treatment, surgical approaches, and radiotherapy.
Key Points
1. Internal Medicine Textbook
Reference: A 2007 publication serving as a quick-reference guide (PocketMedicine).
Scope: Alphabetically covers diseases from "Abdominal Aortic Aneurysm" to conditions like "Zoster" and everything in between (Cardiology, Neurology, etc.).
Authority: Edited and authored by experts from top medical schools (UCSF, Harvard, Yale).
2. VA Community Care Form (10-10172)
Function: Used to request authorization for medical services or Durable Medical Equipment (DME) outside the VA.
Specifics: Requires detailed coding (ICD-10, CPT/HCPCS).
Special Sections: Includes specific criteria for Home Oxygen therapy and Diabetic Footwear (requires a specific "Risk Score" based on sensory loss and circulation).
3. Breast Cancer Introduction (Educational Presentation)
Epidemiology: Breast cancer is the most common cancer in women; lifetime risk is 12.5% (1 in 8).
Screening: Mammograms recommended annually starting at age 40 for average risk; MRI recommended for high risk.
Diagnostics: MRI is highly sensitive for detecting occult malignancies (3-5%) that mammograms miss, especially in dense breasts.
4. WHO Guidelines for Management of Breast Cancer
Protocol: A 2006 clinical manual for diagnosis and treatment.
Staging: Uses the TNM system (Tumor, Nodes, Metastasis).
Treatment: Covers adjuvant systemic therapy (chemo/hormonal), surgical guidelines (mastectomy vs. lumpectomy), and radiotherapy.
Topics and Headings
Medical Reference & Literature
Internal Medicine: Structure and Contents
Clinical Textbook Authorship and Affiliations
Health Administration & Policy
Veterans Affairs (VA) Authorization Process
Community Care Provider Requirements
Medical Coding (ICD-10 and CPT)
Durable Medical Equipment (DME) Assessment
Oncology: Epidemiology & Screening
Breast Cancer Statistics and Risk Factors
Anatomy and Lymphatic Drainage
Mammography vs. MRI Sensitivity
American Cancer Society Screening Guidelines
Clinical Practice & Treatment
WHO Guidelines for Breast Cancer Management
Diagnosis and Staging (TNM)
Adjuvant and Neoadjuvant Therapy
Surgical and Radiotherapy Protocols
Questions for Review
Textbook: Who is the editor of the "Internal Medicine" textbook, and what year was it published by Cambridge University Press?
VA Form: What is the specific form number used to request Durable Medical Equipment (DME) for a Veteran?
Breast Cancer: According to the presentation, what is the lifetime risk of a woman developing invasive breast cancer?
Screening: What imaging modality is recommended in addition to mammography for women at high risk for breast cancer?
Guidelines: Which organization published the "Guidelines for management of breast cancer" included in this text, and in what year?
Easy Explanation
This collection of text is like a Medical Toolkit containing four different types of tools:
The Dictionary (Textbook): This is the "Internal Medicine" book. It lists almost every disease and condition so a doctor can look up what a disease is and how it generally works.
The Permission Slip (VA Form): This is the paperwork a doctor fills out to ask the government (VA) for permission and money to send a Veteran to a private doctor or to get them special equipment like oxygen tanks.
The Lecture (Breast Cancer Intro): This is a slide deck that teaches the "basics" of breast cancer: how common it is, who gets it, and how doctors look for it using mammograms and MRIs.
The Rulebook (WHO Guidelines): This is a strict instruction manual telling doctors exactly how to treat breast cancer—what drugs to use, what surgery to do, and how to radiate the patient—based on standards set by the World Health Organization.
Presentation Outline
Slide 1: Overview of Medical Resources
Introduction to four components: Reference, Admin, Education, and Clinical Protocols.
Slide 2: The "Internal Medicine" Textbook
Purpose: A-Z quick reference for clinicians.
Key Features: Covers all specialties (Cardiology to Neurology).
Context: 2007 publication by Cambridge University Press.
Slide 3: VA Community Care Authorization
Form: VA Form 10-10172 (March 2025).
Function: Requesting non-VA care and equipment.
Requirements: Medical necessity must be proven with codes and specific assessments (e.g., Diabetic Foot Risk Scores).
Slide 4: Breast Cancer - The Basics (Education)
Source: Mayo Clinic Presentation.
Stats: 12.5% lifetime risk (1 in 8 women).
Screening: Mammogram at age 40; MRI for high risk.
Technology: MRI detects cancer mammograms miss.
Slide 5: Breast Cancer - The Management (WHO Guidelines)
Source: WHO Eastern Mediterranean (2006).
Focus: Clinical treatment pathways.
Key Areas: Diagnosis, Staging (TNM), Surgery, Chemotherapy, and Radiotherapy.
Slide 6: Summary
These documents represent the full cycle of care:
Knowledge: The Textbook.
Access: The VA Form.
Understanding: The Presentation.
Action: The WHO Guidelines....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/nejpulrp-2874/data/document.pdf", "num_examples": 80, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/nejpulrp- /home/sid/tuning/finetune/backend/output/nejpulrp-2874/data/nejpulrp-2874.json...
|
null
|
queued
|
1769633586
|
1769641059
|
NULL
|
/home/sid/tuning/finetune/backend/output/nejpulrp- /home/sid/tuning/finetune/backend/output/nejpulrp-2874/adapter...
|
False
|
Edit
Delete
|
|
95c33450-9b76-49bd-bee0-cca1426ebcb0
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
hmemzaqa-3555
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Chapter 3. Breast Canc
|
Chapter 3. Breast Cancer.pdf
|
/home/sid/tuning/finetune/backend/output/hmemzaqa- /home/sid/tuning/finetune/backend/output/hmemzaqa-3555/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Document Description
The provided text is a colle Document Description
The provided text is a collection of five distinct medical and administrative documents. The first document is the front matter of the "Internal Medicine" textbook published by Cambridge University Press in 2007, which serves as an encyclopedic reference guide listing hundreds of medical conditions and the affiliations of its editors. The second document is the "Community Care Provider - Medical" and DME request forms (VA Form 10-10172, March 2025), used to authorize Veterans for community care or durable medical equipment based on strict medical necessity criteria. The third document is a medical presentation titled "An Introduction to Breast Cancer" by Dr. Katherine S. Tzou (Mayo Clinic), which details the epidemiology, anatomy, and screening modalities (mammography vs. MRI). The fourth document contains the "Guidelines for Management of Breast Cancer" published by the WHO Regional Office for the Eastern Mediterranean (2006), offering clinical protocols for diagnosis, staging, and treatment. Finally, the fifth document is "Chapter 3. Breast Cancer" from a broader publication (DCP3), which analyzes global disparities in breast cancer outcomes and introduces resource-stratified guidelines (BHGI) to improve care in low- and middle-income countries.
Key Points
1. Internal Medicine Textbook
Reference: A 2007 pocket guide covering an alphabetical list of diseases from "Abdominal Aortic Aneurysm" to "Zoster."
Authority: Authored by experts from top institutions like UCSF, Harvard, and Yale.
Scope: Covers all major specialties including cardiology, neurology, and infectious diseases.
2. VA Community Care Form (10-10172)
Purpose: An administrative form to request authorization for medical services or DME (like oxygen or therapeutic shoes) outside the VA.
Requirements: Demands ICD-10 diagnosis codes, CPT/HCPCS procedure codes, and clinical documentation.
Specifics: Includes detailed criteria for Diabetic Footwear (Risk Scores based on sensory loss/circulation) and Home Oxygen (flow rates).
3. Breast Cancer Introduction (Educational)
Epidemiology: Breast cancer is the most common cancer in women; lifetime risk is 12.5% (1 in 8).
Screening: Annual mammograms recommended starting at age 40 for average risk; MRI recommended for high risk or dense breasts.
Diagnostics: MRI detects ~3-5% of contralateral malignancies missed by mammograms.
4. WHO Guidelines (Clinical Management)
Protocol: A clinical manual for diagnosis, treatment, and follow-up.
Staging: Utilizes the TNM (Tumor, Nodes, Metastasis) system.
Treatment: Details adjuvant systemic therapy, neoadjuvant chemotherapy, surgical guidelines (mastectomy vs. breast conserving), and radiotherapy.
5. Global Health Strategies (DCP3 Chapter)
Problem: Mortality rates are rising in low- and middle-income countries (LMICs) due to late-stage presentation.
Solution: Breast Health Global Initiative (BHGI) guidelines.
Stratification: Resources are divided into four levels: Basic, Limited, Enhanced, and Maximal, to help countries implement feasible care based on their budget and infrastructure.
Topics and Headings
Medical Reference & Literature
Internal Medicine: Textbook Structure and Contents
Editorial Authority and Academic Affiliations
Health Administration & Policy
Veterans Affairs (VA) Authorization Process
Medical Coding and Billing (ICD-10, CPT)
DME Assessment and Diabetic Footwear Criteria
Oncology: Education & Screening
Breast Cancer Epidemiology and Risk Factors
Anatomy and Lymphatic Drainage
Screening Modalities: Mammography vs. MRI
Clinical Practice & Management
WHO Guidelines: Diagnosis and Staging (TNM)
Treatment Protocols: Systemic, Surgical, and Radiotherapy
Pathology Handling and Reporting
Global Health & Economics
Global Disparities in Breast Cancer Outcomes
Resource-Stratified Guidelines (BHGI)
Cost-Effectiveness in Low- and Middle-Income Countries
Questions for Review
Textbook: Who is the primary editor of the "Internal Medicine" textbook published in 2007?
VA Form: What is the specific "Risk Score" required on the VA form for a diabetic patient to qualify for therapeutic footwear?
Breast Cancer (Intro): According to the Mayo Clinic presentation, what is the lifetime risk of a woman developing invasive breast cancer?
Screening: At what age does the American Cancer Society recommend annual mammogram screening begin for women at average risk?
Guidelines (WHO): What staging system is outlined in the WHO guidelines to describe the extent of disease?
Global Health: Name the four resource levels defined by the Breast Health Global Initiative (BHGI) to stratify care based on available resources.
Easy Explanation
This collection of text represents a complete "Medical Toolkit" containing five different types of tools:
The Dictionary (Textbook): This is the "Internal Medicine" book. It lists almost every disease so a doctor can quickly look up what a condition is.
The Permission Slip (VA Form): This is the paperwork a doctor fills out to ask the government for permission and money to send a Veteran to a private doctor or to get them special equipment like oxygen.
The Lecture (Breast Intro): This is a slide deck that teaches the "basics" of breast cancer: how common it is, who gets it, and how to look for it using mammograms and MRIs.
The Rulebook (WHO Guidelines): This is a strict instruction manual telling doctors exactly how to treat breast cancer—what drugs to use, what surgery to do, and how to radiate the patient.
The Business Plan (DCP3 Chapter): This is a strategy document for countries with less money. It explains how to set up a breast cancer program that works within their budget, focusing on the most important steps first (like Clinical Breast Exams instead of expensive mammograms).
Presentation Outline
Slide 1: Overview of Medical Resources
Introduction to five components: Reference, Admin, Education, Clinical Protocols, and Global Strategy.
Slide 2: The "Internal Medicine" Textbook
Purpose: A-Z quick reference for clinicians.
Key Features: Covers all specialties (Cardiology to Neurology).
Context: 2007 publication by Cambridge University Press.
Slide 3: VA Community Care Authorization
Form: VA Form 10-10172 (March 2025).
Function: Requesting non-VA care and equipment.
Requirements: Medical necessity proven with codes and specific assessments (e.g., Diabetic Foot Risk Scores).
Slide 4: Breast Cancer - The Basics (Education)
Source: Mayo Clinic Presentation.
Stats: 12.5% lifetime risk (1 in 8 women).
Screening: Mammogram at age 40; MRI for high risk.
Technology: MRI detects cancer mammograms miss.
Slide 5: Clinical Management (WHO Guidelines)
Source: WHO Eastern Mediterranean (2006).
Focus: Clinical treatment pathways.
Key Areas: Diagnosis, Staging (TNM), Surgery, Chemotherapy, and Radiotherapy.
Slide 6: Global Health Strategies (DCP3)
Challenge: High mortality in low-resource settings due to late detection.
Solution: BHGI Guidelines.
Framework: Four levels of resources (Basic to Maximal) to guide implementation.
Slide 7: Summary
These documents represent the full spectrum of care:
Knowledge: The Textbook.
Access: The VA Form.
Understanding: The Presentation.
Treatment: The WHO Guidelines.
Strategy: The Global Health Chapter....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/hmemzaqa-3555/data/document.pdf", "num_examples": 35, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/hmemzaqa- /home/sid/tuning/finetune/backend/output/hmemzaqa-3555/data/hmemzaqa-3555.json...
|
null
|
queued
|
1769633767
|
1769648509
|
NULL
|
/home/sid/tuning/finetune/backend/output/hmemzaqa- /home/sid/tuning/finetune/backend/output/hmemzaqa-3555/adapter...
|
False
|
Edit
Delete
|
|
ecfdb462-f02c-4f4d-aea7-b731c2bd6ce0
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
uvleovlc-6852
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Breast cancer
|
Breast cancer
|
/home/sid/tuning/finetune/backend/output/uvleovlc- /home/sid/tuning/finetune/backend/output/uvleovlc-6852/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Description of the PDF File
This docu 1. Complete Description of the PDF File
This document serves as an educational guide on breast cancer, outlining its definition, causes, symptoms, diagnosis, treatment, and prevention. It explains that breast cancer is caused by the abnormal growth of cells in breast tissue, affecting both men and women, though it is more common in women (with a statistic of 1 in 8 women at risk). The text details the importance of distinguishing between benign and malignant tumors and highlights that while lumps are a common sign, they do not always indicate cancer. It provides a thorough overview of diagnostic methods, including breast self-examinations, physical exams, and mammograms, while emphasizing the importance of early detection. Furthermore, the document lists risk factors such as age, genetics, and lifestyle choices, and outlines potential complications if the disease spreads to other organs. Treatment options are discussed alongside preventive measures like maintaining a healthy lifestyle and breastfeeding. Finally, the document addresses common frequently asked questions and debunks popular misconceptions regarding breast cancer causes and detection methods.
2. Key Topics & Headings
Here are the main headings found in the document to help organize the information:
Overview of Breast Cancer
Definition of Cancer (Benign vs. Malignant)
Statistics & Risk Factors
Types of Breast Cancer
Symptoms & Warning Signs
When to See a Doctor
Diagnosis Methods
Breast Self-Examination (Methods)
Physical Examination
Mammography
Complications
Treatment Options
Prevention (Primary & Secondary)
Frequently Asked Questions (FAQs)
Common Misconceptions vs. Truth
3. Key Points (Easy Explanation)
These are the most important takeaways from the document, simplified for easy understanding:
What is it? Breast cancer is the uncontrollable growth of abnormal cells in breast tissue. It can happen to anyone but is more common in women.
Not all lumps are cancer: Finding a lump does not mean you have cancer; it could be a cyst or an infection. However, a doctor must check it.
Early detection saves lives: The best way to survive breast cancer is to find it early. This is done through self-exams and mammograms.
Main Symptoms: Look for a solid lump (usually painless), changes in breast shape, nipple discharge (especially blood), or skin changes (wrinkling/itching).
Who is at risk? Risk factors include being a woman, older age (over 55), family history, obesity, alcohol use, and never having been pregnant.
Diagnosis:
Self-Exam: Check monthly 3-5 days after your period.
Mammogram: An X-ray of the breast. Women over 40 should get one yearly.
Prevention: Live a healthy lifestyle (exercise, eat well), breastfeed your children, and avoid smoking.
Myths: Wearing bras, using deodorant, or getting hit in the chest do not cause breast cancer.
4. Important Questions & Answers (Study Guide)
Use these questions to review the key information:
Q: What is the difference between a benign tumor and a malignant tumor?
A: A benign tumor is not cancerous. A malignant tumor is cancerous and has the ability to spread to other parts of the body.
Q: What are the three main methods for diagnosing breast cancer?
A: 1) Breast self-examination, 2) Physical examination by a doctor, and 3) Mammography (X-ray).
Q: How often should women perform a breast self-exam?
A: Routinely every month, three to five days after the menstrual cycle begins.
Q: At what age are women generally advised to start getting annual mammograms?
A: Starting at age 40 (or earlier if there is a family history).
Q: Can men get breast cancer?
A: Yes. Although it is more common in women, men can get it too. It is often more dangerous in men because they do not expect it and delay seeing a doctor.
Q: Does a mammogram treat cancer?
A: No, a mammogram is only a diagnostic tool (a test) to detect cancer, not a treatment.
Q: Does wearing a bra cause breast cancer?
A: No, studies have not proven a link between wearing a bra and developing breast cancer.
5. Presentation Outline
If you were to present this information, you could structure your slides like this:
Slide 1: Title
Breast Cancer Awareness
Definition, Symptoms, and Prevention
Slide 2: What is Breast Cancer?
Abnormal growth of cells in breast tissue.
Can be benign (non-cancerous) or malignant (cancerous).
Most common type: Ductal carcinoma in situ (starts in milk ducts).
Slide 3: Statistics & Risk Factors
Statistic: 1 in 8 women are at risk.
Risks: Gender (female), Age (55+), Genetics, Family history, Obesity, Alcohol, Delayed pregnancy.
Slide 4: Symptoms
Solid, non-painful lump in breast/armpit.
Change in breast size or shape.
Nipple discharge or inverted nipple.
Skin wrinkling, itching, or redness.
Note: Most early stages have no symptoms.
Slide 5: Diagnosis & Early Detection
Self-Exam: Monthly (lying down and standing in front of a mirror).
Doctor Exam: Physical check-up.
Mammogram: X-ray imaging (Yearly after age 40).
Slide 6: Treatment
Depends on stage and health.
Options: Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy.
Slide 7: Prevention
Primary: Healthy diet, exercise, maintain weight, breastfeeding, avoid smoking.
Secondary: Regular self-exams and screenings.
Slide 8: Myths vs. Facts
Myth: Deodorants cause cancer. Fact: No evidence.
Myth: Biopsies cause cancer to spread. Fact: Biopsies identify the cancer type.
Myth: Only women get it. Fact: Men can get it too.
Slide 9: Conclusion
Early detection is the key to recovery.
Consult a doctor immediately if you notice any changes.
Contact: Hpromotion@moh.gov.sa...
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/uvleovlc-6852/data/document.pdf", "num_examples": 5, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/uvleovlc- /home/sid/tuning/finetune/backend/output/uvleovlc-6852/data/uvleovlc-6852.json...
|
null
|
queued
|
1769633919
|
1769635120
|
NULL
|
/home/sid/tuning/finetune/backend/output/uvleovlc- /home/sid/tuning/finetune/backend/output/uvleovlc-6852/adapter...
|
False
|
Edit
Delete
|
|
b7214e39-3b5d-42c0-8211-432222c0ee90
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
dudctnwy-4347
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Breast Cancer and You_
|
Breast Cancer and You_ENG_.pdf
|
/home/sid/tuning/finetune/backend/output/dudctnwy- /home/sid/tuning/finetune/backend/output/dudctnwy-4347/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Document Description
The provided text is an exce Document Description
The provided text is an excerpt from the seventh edition of the handbook titled "Breast Cancer and You: A guide for people living with breast cancer," published by the Canadian Breast Cancer Network (CBCN) in 2022. This document serves as a comprehensive educational resource designed for patients, families, and caregivers navigating a breast cancer diagnosis. It acknowledges the contributions of medical oncologists, healthcare professionals, and a volunteer board of directors who have personally experienced breast cancer. The handbook covers the full spectrum of the disease, starting with basic anatomy and biology of the breast to explain how cancer develops. It details known risk factors (both lifestyle-related and genetic), addresses common myths, and includes specific information on breast cancer in men. A significant portion of the text is dedicated to screening and diagnosis, explaining the differences between clinical exams, self-awareness, mammograms, and biopsies. Furthermore, it provides practical tools for patients to understand their specific pathology reports, including tumor classification (TNM staging), hormone receptor status, and subtypes (such as Triple Negative or HER2+). The document includes printable worksheets to help individuals track their diagnosis and treatment plans, covering surgery, radiation, chemotherapy, hormonal therapy, and reconstruction. Ultimately, the guide aims to empower patients with knowledge to reduce anxiety, facilitate informed decision-making with their healthcare teams, and improve their quality of life during and after treatment.
Key Points & Main Topics
Here are the main headings and topics extracted from the content to structure your understanding:
Introduction & Purpose
A handbook to empower patients with knowledge.
Emphasizes that early detection and improved treatments lead to high survival rates.
Goal: Reduce overwhelm and help patients participate in their care.
Understanding Breast Anatomy
Normal Breast Structure: Contains lobules (glands), ducts (tubes), fatty tissue, and connective tissue.
The Lymphatic System: Fluid (lymph) is filtered through lymph nodes. Key node groups include axillary (armpit), internal mammary (chest), and supraclavicular (collarbone).
Hormones: Estrogen and progesterone influence breast cell activity from puberty through menopause.
Causes and Risk Factors
How Cancer Starts: Mutations in DNA cause cells to divide uncontrollably. Can be inherited (e.g., BRCA genes) or acquired over a lifetime.
Risk Factors:
Modifiable: Smoking, alcohol, obesity, physical inactivity.
Non-modifiable: Age, family history, genetics, dense breast tissue.
Demographics: Higher rates in Caucasian women; higher rates of aggressive subtypes in Black and African Canadian women; higher genetic risk in Ashkenazi Jewish women.
Men & Breast Cancer: Rare (<1%) but possible. Usually occurs in men aged 60-70.
Screening and Detection
Mammography: The standard screening tool using X-rays (2D or 3D tomosynthesis).
Screening Mammogram: For women without symptoms.
Diagnostic Mammogram: For women with lumps or symptoms.
Clinical Breast Exam (CBE): Performed by a healthcare professional.
Breast Self-Awareness (BSA): Knowing how your breasts normally look and feel to notice changes (replaces the old rigid "self-exam" routine).
Age Guidelines:
40-49: Discuss risks/benefits with a doctor.
50-74: Mammogram every 2 years.
Diagnosis & Staging
Biopsy: Taking a sample of breast tissue to confirm cancer.
Tumor Classifications (The Subtypes):
Ductal vs. Lobular: Where the cancer starts.
Invasive vs. In Situ: Whether it has spread.
Receptor Status: Hormone Receptor-positive (HR+) vs. HER2+ vs. Triple Negative.
Staging (TNM System):
T: Size of the Tumor.
N: Involvement of Lymph Nodes.
M: Metastasis (spread to distant parts of the body).
Stages: Range from Stage 0 (non-invasive) to Stage IV (metastatic).
Treatment Overview
Multidisciplinary Approach: Surgery, Radiation, Chemotherapy, Hormonal Therapy, Targeted Therapy, and Immunotherapy.
Surgery: Lumpectomy (removing lump) vs. Mastectomy (removing breast).
Reconstruction: Options for rebuilding the breast (implants or autologous/flap techniques).
Patient Tools
Worksheets: Included in the guide to help patients record their specific diagnosis (Stage, Grade, Receptor status) and planned treatment regimen.
Study & Review Questions
Here are some questions you can use to test your understanding of the material or to create a quiz:
Anatomy: What are the two main components of the breast where milk is produced and transported?
Answer: Lobules (produce milk) and Ducts (transport milk).
Risk Factors: Name two non-modifiable risk factors and two lifestyle-related risk factors for breast cancer.
Answer (Non-modifiable): Age, family history, genetics (BRCA).
Answer (Lifestyle): Smoking, alcohol, obesity, lack of physical activity.
Screening: What is the difference between a screening mammogram and a diagnostic mammogram?
Answer: Screening is for asymptomatic women to check for early signs; Diagnostic is for women who have symptoms (lumps, pain) or an abnormal screening result.
Diagnosis: What does "TNM" stand for in breast cancer staging?
Answer: Tumor (size), Nodes (lymph node involvement), Metastasis (distant spread).
Myths: True or False? If you have a family history of breast cancer, you will definitely develop it.
Answer: False. A family history increases risk, but does not guarantee you will get it.
Demographics: Which demographic group has the highest risk of carrying the BRCA1/2 gene mutation?
Answer: Women of Ashkenazi Jewish descent.
Men: Can men get breast cancer? What is the most common type?
Answer: Yes. Invasive ductal carcinoma is the most common type in men.
Presentation Outline (Easy Explanation)
If you need to present this information to a group, you can use this simple structure:
Slide 1: Title & Introduction
Title: Understanding Breast Cancer: A Patient’s Guide.
Source: Canadian Breast Cancer Network (CBCN) – 7th Edition.
Key Message: Knowledge is power. Understanding your diagnosis helps you work with your healthcare team.
Slide 2: The Healthy Breast
Visual Idea: Show Figure 1 (Breast anatomy).
Talking Points:
Breasts are made of glands (lobules), tubes (ducts), and fat.
Hormones (Estrogen/Progesterone) affect how breast cells grow.
The lymphatic system acts as a drainage system; cancer often travels to lymph nodes first.
Slide 3: Who Gets Breast Cancer?
Risk Factors:
Things you can't change: Age, genetics, family history.
Things you CAN change: Quitting smoking, reducing alcohol, staying active.
Myths vs. Facts:
Myth: Antiperspirants cause cancer. (Fact: No scientific proof).
Myth: Only women get it. (Fact: Men can get it too, though it is rare).
Slide 4: Early Detection & Screening
Mammograms: X-rays of the breast. Recommended every 2 years for women aged 50-74.
Breast Self-Awareness: Know what is normal for you. Look for lumps, changes in shape, or skin texture.
Why it matters: Early detection leads to easier treatment and better outcomes.
Slide 5: Diagnosis: What do the results mean?
Biopsy: The only way to confirm cancer.
Hormone Status: Is the cancer fueled by Estrogen/Progesterone (ER+/PR+)?
HER2 Status: Is the cancer making too much of the HER2 protein?
Staging (TNM): Describes the size (T), lymph node involvement (N), and spread (M).
Slide 6: Treatment Planning
Surgery: Removing the tumor (Lumpectomy) or the breast (Mastectomy).
Other Therapies:
Chemotherapy: Kills fast-growing cells.
Radiation: Kills remaining cancer cells in the breast area.
Hormonal Therapy: Blocks hormones to stop cancer growth.
Reconstruction: Options available to rebuild the breast.
Slide 7: Conclusion
Every patient is different.
Use the workbook in the guide to track your specific plan.
You are not alone—support groups and resources are available....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/dudctnwy-4347/data/document.pdf", "num_examples": 502, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/dudctnwy- /home/sid/tuning/finetune/backend/output/dudctnwy-4347/data/dudctnwy-4347.json...
|
null
|
queued
|
1769634022
|
1769663044
|
NULL
|
/home/sid/tuning/finetune/backend/output/dudctnwy- /home/sid/tuning/finetune/backend/output/dudctnwy-4347/adapter...
|
False
|
Edit
Delete
|
|
ce78cb50-038b-4140-a7d7-2831829c287e
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
llidsuvi-1216
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Breast Cancer
|
Breast Cancer
|
/home/sid/tuning/finetune/backend/output/llidsuvi- /home/sid/tuning/finetune/backend/output/llidsuvi-1216/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Complete Document Description
The provided text c Complete Document Description
The provided text comprises two complementary resources regarding breast cancer: a patient handbook titled "Breast Cancer and You" (7th Edition) by the Canadian Breast Cancer Network and a clinical review article titled "Clinical Diagnosis and Management of Breast Cancer." The patient guide serves as a supportive educational tool for individuals diagnosed with breast cancer, explaining the basics of breast anatomy, the role of hormones, and the emotional impact of a diagnosis. It dispels common myths, outlines risk factors (including demographics and lifestyle), and provides a detailed breakdown of screening methods like mammography and self-awareness. It further offers practical tools, such as worksheets to understand pathology reports and treatment plans covering surgery, radiation, and chemotherapy.
Complementing the patient perspective, the clinical article delves into the medical community's shift toward "precision medicine" and personalized treatment. It discusses advanced diagnostic protocols, such as the use of Digital Breast Tomosynthesis (3D mammography) to reduce false positives and the utilization of MRI and PET/CT for staging. It elaborates on the critical importance of tumor biomarkers (ER, PR, HER2) and gene expression assays (like Oncotype DX) in determining prognosis and therapy. The text details multidisciplinary treatment strategies, including surgical advances like radioactive seed localization and nipple-sparing mastectomy, as well as modern radiation techniques like hypofractionation and accelerated partial breast irradiation (APBI). Together, these documents provide a holistic view of breast cancer management, ranging from patient empowerment and understanding to the latest evidence-based clinical interventions.
Key Points, Topics, and Headings
1. Understanding the Disease
Anatomy & Biology: Structure of lobules, ducts, and lymph nodes; the role of estrogen and progesterone.
Epidemiology & Risk: Differences in risk based on age, genetics (BRCA), and ethnicity (e.g., higher Triple Negative rates in Black women).
Breast Cancer in Men: Rare (<1%) but presents similarly to post-menopausal women; often diagnosed at a later stage.
2. Screening and Diagnosis
Screening Modalities:
Mammography: Standard of care; reduction in mortality.
Digital Breast Tomosynthesis (3D): Reduces false positives and increases detection rates compared to 2D.
MRI: Recommended for high-risk patients (>20% lifetime risk) or dense breasts.
Biopsy & Pathology: Fine-needle aspiration, core biopsy, and the assessment of margins.
Biomarkers: Testing for Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 status.
Genomic Testing: Using multi-gene assays (e.g., Oncotype DX, MammaPrint) to predict recurrence and guide chemotherapy decisions.
3. Staging and Imaging
TNM Staging System: Tumor size (T), Nodal involvement (N), and Metastasis (M).
Advanced Imaging: The role of MRI in surgical planning and neoadjuvant chemotherapy response; use of PET/CT for advanced (Stage IIIB/C or IV) disease.
4. Treatment Modalities
Surgery:
Breast-Conserving Surgery (BCS): Lumpectomy with radiation.
Mastectomy: Skin-sparing and nipple-sparing options.
Axillary Management: Sentinel Lymph Node Biopsy (SLNB) vs. Axillary Lymph Node Dissection (ALND); the move away from full dissection in patients with 1-2 positive nodes (ACOSOG Z0011 trial).
Localization: Use of radioactive seeds or wires to guide tumor removal.
Medical Oncology:
Chemotherapy: Anthracyclines and taxanes; role in neoadjuvant (before surgery) and adjuvant (after surgery) settings.
Targeted Therapy: HER2-directed treatments (Trastuzumab, Pertuzumab).
Endocrine Therapy: Aromatase inhibitors and Tamoxifen for HR+ cancers.
Radiation Therapy:
Whole Breast Irradiation (WBI): Standard treatment post-lumpectomy.
Hypofractionation: Shorter treatment courses (fewer, larger doses) with equal efficacy.
Accelerated Partial Breast Irradiation (APBI): Treating only the tumor bed, reducing treatment time to 1 week.
5. The Future of Care
Precision Medicine: Combining genomic data with imaging to create personalized treatment plans.
Patient Empowerment: Using knowledge to reduce anxiety and participate in shared decision-making.
Study Questions & Key Points
Screening Technology: How does Digital Breast Tomosynthesis (3D mammography) improve upon traditional 2D mammography?
Key Point: It reduces false-positive recalls and increases cancer detection rates, though it involves a slightly higher radiation dose unless synthetic 2D images are used.
Surgical Advances: According to the ACOSOG Z0011 trial, when is a full Axillary Lymph Node Dissection (ALND) no longer necessary?
Key Point: It is often not necessary for women with clinical T1-T2 tumors and 1-2 positive sentinel nodes who are undergoing breast-conserving surgery and whole-breast radiation.
Genomic Testing: What is the purpose of assays like Oncotype DX or MammaPrint?
Key Point: They analyze the expression of multiple genes to predict the risk of distant recurrence, helping doctors decide if a patient will benefit from chemotherapy.
Radiation Techniques: What is the difference between Hypofractionated Whole Breast Irradiation and Accelerated Partial Breast Irradiation (APBI)?
Key Point: Hypofractionation uses larger doses over a shorter time (e.g., 3-4 weeks) to treat the whole breast. APBI treats only the area around the tumor (lumpectomy site) over an even shorter period (e.g., 1 week).
High-Risk Patients: Which imaging modality is recommended as an adjunct to mammography for women with a lifetime breast cancer risk greater than 20%?
Key Point: Breast MRI.
Staging: For which stages of breast cancer is a PET/CT scan recommended?
Key Point: It is optional/recommended for locally advanced (Stage IIIB/C) or metastatic (Stage IV) disease, but not for early-stage (Stage I or II) patients without symptoms.
Easy Explanation: Presentation Outline
Title: From Detection to Precision Treatment: Understanding Modern Breast Cancer Care
Slide 1: Introduction
Breast cancer care is shifting from a "one-size-fits-all" approach to Personalized/Precision Medicine.
Goal: Treat the specific tumor biology while minimizing side effects and preserving quality of life.
Slide 2: Detection & Screening
The Gold Standard: Mammography remains the primary tool for saving lives.
New Tech: 3D Mammography (Tomosynthesis) gives doctors a clearer view and reduces "false alarms."
For High Risk: Women with strong family history or genetic mutations (BRCA) need MRI scans in addition to mammograms.
Slide 3: Diagnosing the Specifics
It’s not just "breast cancer"—it’s a subtype.
Biomarkers: We test for ER (Estrogen), PR (Progesterone), and HER2.
ER/PR+: Fueled by hormones (treated with hormone blockers).
HER2+: Aggressive but targetable (treated with antibodies like Herceptin).
Triple Negative: Needs chemotherapy.
Genomic Tests: We can now analyze the tumor's genes to predict if chemotherapy is actually needed.
Slide 4: Treatment: Surgery & Radiation
Less Invasive Surgery:
Lumpectomy (removing just the lump) is often as safe as mastectomy (removing the breast) when followed by radiation.
Radioactive seeds help surgeons find the tumor without wires.
Faster Radiation:
We used to treat for 6-7 weeks. Now, many patients can finish in 3-4 weeks (Hypofractionation) or even 1 week (Partial Breast).
Slide 5: Systemic (Drug) Therapy
Targeted Therapy: Drugs that seek out specific cancer cells (e.g., HER2 drugs).
Chemotherapy: Used for aggressive tumors or high-risk features to kill microscopic cells.
Endocrine Therapy: Long-term pills (like Tamoxifen or Aromatase Inhibitors) for hormone-positive cancers to prevent recurrence.
Slide 6: Patient Support
Understanding your diagnosis empowers you.
Use support groups and resources (like the CBCN guide) to navigate the emotional and physical journey.
Key Takeaway: Advances in screening and personalized treatment have significantly improved survival and quality of life....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/llidsuvi-1216/data/document.pdf", "num_examples": 57, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/llidsuvi- /home/sid/tuning/finetune/backend/output/llidsuvi-1216/data/llidsuvi-1216.json...
|
null
|
queued
|
1769634189
|
1769639574
|
NULL
|
/home/sid/tuning/finetune/backend/output/llidsuvi- /home/sid/tuning/finetune/backend/output/llidsuvi-1216/adapter...
|
False
|
Edit
Delete
|
|
66302cc0-76d7-446f-9a9c-ebbe45cacc41
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
solwedka-6648
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Understanding_Breast_C
|
Understanding_Breast_Changes.pdf
|
/home/sid/tuning/finetune/backend/output/solwedka- /home/sid/tuning/finetune/backend/output/solwedka-6648/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Description of the PDF File
This docu 1. Complete Description of the PDF File
This document serves as a comprehensive educational guide on breast cancer, covering its definition, statistics, risk factors, symptoms, diagnostic methods, treatment options, and prevention strategies. It begins by defining cancer broadly and then focuses specifically on breast cancer, explaining it as the uncontrollable growth of cells in breast tissue that can potentially spread. The text highlights that while breast lumps are a common sign, they are not always cancerous and may be caused by cysts or infections. It outlines critical diagnostic procedures, including breast self-examinations (with specific instructions for lying down and standing), physical exams by doctors, and mammograms, which are described as the most accurate early detection method. Furthermore, the guide lists various risk factors such as age, genetics, and lifestyle choices, and details the complications that can arise if the cancer spreads to vital organs. Treatment options are summarized alongside preventive measures like healthy living and breastfeeding. Finally, the document addresses frequently asked questions and debunks common myths, clarifying that factors like wearing bras or using deodorants do not cause breast cancer.
2. Key Topics & Headings
These are the main sections and headings found in the document to help organize the information:
Overview of Breast Cancer
Definition of Cancer and Breast Cancer
Statistics (Risk Prevalence)
Types of Breast Cancer (e.g., Ductal Carcinoma in Situ)
Causes and Risk Factors
Symptoms and Warning Signs
When to See a Doctor
Diagnosis Methods
Breast Self-Examination (Techniques: Lying Down & Standing)
Physical Examination
Mammography
Complications
Treatment Options
Prevention (Primary and Secondary)
Frequently Asked Questions (FAQs)
Misconceptions vs. Truths
3. Key Points (Easy Explanation)
Here are the most important takeaways from the document, simplified for quick understanding:
What is Breast Cancer? It is a disease caused by abnormal changes in the cells of breast tissue, causing them to grow uncontrollably and potentially spread.
Not All Lumps are Cancer: Finding a lump does not mean you have cancer. Lumps can often be benign cysts or caused by infections.
Who is at Risk? It mostly affects women (1 in 8 women are at risk), but men can get it too. Higher risks include being over 55, having a family history, obesity, and alcohol use.
Key Symptoms: A solid, painless lump in the breast or armpit, changes in breast size/shape, nipple discharge (especially blood), inverted nipples, or skin changes like wrinkling or itching.
Diagnosis:
Self-Exam: Check monthly 3-5 days after your period.
Mammogram: An X-ray of the breast. Women over 40 should have one annually.
Prevention: Maintain a healthy lifestyle (diet, exercise), breastfeed, avoid smoking, and get regular checkups.
Myths: Wearing bras, using deodorant, or getting hit in the chest do not cause breast cancer.
Treatment: Depends on the stage but can include surgery, chemotherapy, radiation, and hormone therapy.
4. Important Questions & Answers (Study Guide)
Use these questions to test your knowledge of the material:
Q: What is the definition of a malignant tumor?
A: A malignant tumor is a cancerous tumor that has the ability to spread to neighboring tissues and other parts of the body.
Q: What are the three main methods for diagnosing breast cancer?
A: 1) Breast self-examination, 2) Physical examination by a doctor, and 3) Mammography.
Q: When is the best time to perform a breast self-examination?
A: Routinely every month, three to five days after the menstrual cycle begins.
Q: At what age are women generally advised to start getting annual mammograms?
A: Starting at age 40 (or earlier if there is a family history of the disease).
Q: Does a mammogram cause cancer to spread?
A: No. This is a misconception. A mammogram uses a very small dose of radiation and breast compression cannot cause cancer to spread.
Q: Can men get breast cancer?
A: Yes. Although less common, men can get breast cancer. It can be more dangerous in men because they often do not expect it and delay seeing a doctor until the disease is advanced.
Q: Is a biopsy dangerous because it causes cancer to spread?
A: No. A biopsy is a safe procedure used to remove a piece of tissue to identify the type of mass. It does not cause the cancer to spread.
5. Presentation Outline
If you need to present this information, you can use this slide structure:
Slide 1: Title
Breast Cancer Awareness
Understanding the Risks, Symptoms, and Prevention
Slide 2: What is Breast Cancer?
Abnormal growth of cells in breast tissue.
Types: Benign (non-cancerous) vs. Malignant (cancerous).
Most common type: Ductal carcinoma in situ (DCIS).
Slide 3: Statistics & Risk Factors
Statistic: 1 in 8 women are at risk.
Key Risks: Gender (female), Age (55+), Genetics, Family history, Obesity, Alcohol consumption, Delayed pregnancy, Not breastfeeding.
Slide 4: Symptoms
Solid, non-painful lump in breast or armpit.
Change in size, shape, or appearance of the breast.
Nipple discharge or inversion.
Skin changes (dimpling, redness, scaling).
Note: In most cases, the patient does not feel pain.
Slide 5: Diagnosis
Self-Exam: Monthly checks (lying down & mirror check).
Doctor Exam: Professional physical check-up.
Mammogram: The most accurate early detection tool (X-ray).
Slide 6: Treatment & Complications
Complications: Spread to lymph nodes or vital organs (brain, liver, lungs).
Treatment: Surgery, Chemotherapy, Radiation, Hormone therapy, Targeted therapy.
Slide 7: Prevention
Primary Prevention: Healthy lifestyle, physical activity, breastfeeding, avoiding smoking.
Secondary Prevention: Regular self-exams and mammograms.
Slide 8: Myths vs. Facts
Myth: Deodorants/Antiperspirants cause cancer.
Fact: No conclusive evidence links them.
Myth: Only women get breast cancer.
Fact: Men can get it too.
Myth: Biopsies spread cancer.
Fact: Biopsies are diagnostic tools and do not spread cancer.
Slide 9: Conclusion
Early detection leads to faster recovery.
Consult a doctor immediately if you notice changes.
...
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/solwedka-6648/data/document.pdf"}...
|
/home/sid/tuning/finetune/backend/output/solwedka- /home/sid/tuning/finetune/backend/output/solwedka-6648/data/solwedka-6648.json...
|
null
|
failed
|
1769634240
|
1769638454
|
NULL
|
/home/sid/tuning/finetune/backend/output/solwedka- /home/sid/tuning/finetune/backend/output/solwedka-6648/adapter...
|
False
|
Edit
Delete
|
|
eca5129b-584f-432c-be16-7adca2a09b90
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
gslpueip-2129
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Types of Breast-Cancer
|
Types of Breast-Cancer.pdf
|
/home/sid/tuning/finetune/backend/output/gslpueip- /home/sid/tuning/finetune/backend/output/gslpueip-2129/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Description of the PDF File
This docu 1. Complete Description of the PDF File
This document serves as a comprehensive educational guide on breast cancer, aiming to raise awareness about the disease's definition, statistics, causes, symptoms, and management. It defines breast cancer as a condition arising from the abnormal growth of cells in breast tissue, distinguishing between benign tumors and malignant ones that can spread to other organs. The text highlights that one in eight women is at risk of developing breast cancer and details the most common type, Ductal carcinoma in situ (DCIS). It provides an in-depth look at risk factors—including age, genetics, and lifestyle choices—and lists potential symptoms such as lumps, nipple discharge, and skin changes. Furthermore, the document outlines critical diagnostic procedures, offering step-by-step instructions for breast self-examinations and explaining the role of mammograms and physical exams. It concludes with information on treatment options (like chemotherapy and surgery), preventive measures (such as healthy living and breastfeeding), and a section dedicated to debunking common myths and answering frequently asked questions to clarify misconceptions about the disease.
2. Key Topics & Headings
These are the main sections covered in the document:
Overview & Definition of Cancer and Breast Cancer
Statistics & Risk Factors
Types of Breast Cancer (DCIS)
Symptoms & Warning Signs
When to See a Doctor
Diagnosis Methods
Breast Self-Examination (Lying Down & Standing)
Physical Examination
Mammography
Complications
Treatment Options
Prevention (Primary & Secondary)
Frequently Asked Questions (FAQs)
Common Misconceptions vs. Truth
3. Key Points (Easy Explanation)
Here are the simplified takeaways from the document:
What it is: Breast cancer is the uncontrollable growth of abnormal cells in breast tissue that can spread to other parts of the body.
Not all lumps are cancer: Finding a lump does not automatically mean you have cancer; lumps can also be cysts or infections.
Early detection is crucial: The best way to survive breast cancer is to find it early using self-exams and mammograms.
Who is at risk? primarily women (1 in 8 risk), but men can get it too. Risks increase with age, family history, obesity, and alcohol use.
Symptoms to watch for: A solid, painless lump; changes in breast shape or size; nipple discharge (especially blood); or skin changes like itching, redness, or wrinkling.
Diagnosis:
Self-Exam: Perform monthly, 3–5 days after your period starts.
Mammogram: An X-ray of the breast. Women over 40 should have one annually.
Prevention: Lead a healthy lifestyle (exercise, diet), breastfeed, avoid smoking, and get regular screenings.
Myths: Wearing bras, using deodorants, or getting hit in the chest do not cause breast cancer.
4. Important Questions & Answers
Use these Q&As to study the material:
Q: What is the difference between a benign tumor and a malignant tumor?
A: A benign tumor is non-cancerous and does not spread. A malignant tumor is cancerous and has the ability to invade surrounding tissues and spread to other organs.
Q: When is the best time to perform a breast self-examination?
A: It should be done routinely every month, three to five days after the menstrual cycle begins.
Q: At what age are women generally advised to start getting annual mammograms?
A: Starting at age 40 (or earlier if there is a family history of breast cancer).
Q: Can men get breast cancer?
A: Yes. Although it is more common in women, men can develop breast cancer. It is often more dangerous in men because they do not expect it and delay seeing a doctor.
Q: Is a mammogram a treatment method?
A: No, a mammogram is a diagnostic tool (an X-ray) used to detect breast cancer, not to treat it.
Q: Do biopsies cause cancer to spread?
A: No. This is a myth. A biopsy is a necessary procedure to remove a sample of tissue to identify the type of mass.
Q: Does wearing an underwire bra increase the risk of breast cancer?
A: No, studies have not proven any relationship between wearing a bra and developing breast cancer.
5. Presentation Outline
If you were presenting this information, here is how you could structure your slides:
Slide 1: Title
Understanding Breast Cancer
Awareness, Detection, and Prevention
Slide 2: What is Breast Cancer?
Abnormal growth of cells in breast tissue.
Two types of tumors: Benign (safe) vs. Malignant (cancerous).
Most common type: Ductal carcinoma in situ (DCIS).
Slide 3: Statistics & Risk Factors
Statistic: 1 in 8 women are at risk.
Major Risks: Gender (female), Age (55+), Genetics/ Family History, Obesity, Alcohol, Late pregnancy/No pregnancy.
Slide 4: Symptoms
Solid, painless lump in breast or armpit.
Change in size, shape, or appearance of the breast.
Nipple discharge (bloody) or inverted nipple.
Skin changes (itching, scaling, wrinkling).
Note: Most patients do not feel pain in early stages.
Slide 5: Diagnosis & Detection
Self-Exam: Monthly check (lying down and in front of a mirror).
Physical Exam: By a trained specialist.
Mammogram: The most accurate early detection method (Yearly after age 40).
Slide 6: Treatment & Complications
Complications: Spread to lymph nodes or vital organs (brain, liver, lungs).
Treatment: Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy.
Slide 7: Prevention
Primary: Healthy diet, exercise, maintain weight, breastfeeding, avoid smoking.
Secondary: Regular self-exams and mammograms.
Slide 8: Myths vs. Facts
Myth: Deodorants cause cancer. Fact: No evidence.
Myth: Bras cause cancer. Fact: No relationship proven.
Myth: Biopsies spread cancer. Fact: Biopsies are diagnostic and safe.
Slide 9: Conclusion
Early detection saves lives.
Consult a doctor immediately if you notice any changes.
For more info: Hpromotion@moh.gov.sa...
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/gslpueip-2129/data/document.pdf"}...
|
/home/sid/tuning/finetune/backend/output/gslpueip- /home/sid/tuning/finetune/backend/output/gslpueip-2129/data/gslpueip-2129.json...
|
null
|
failed
|
1769634359
|
1769636466
|
NULL
|
/home/sid/tuning/finetune/backend/output/gslpueip- /home/sid/tuning/finetune/backend/output/gslpueip-2129/adapter...
|
False
|
Edit
Delete
|
|
13edb6ea-942d-42a0-9542-39bea27be20b
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
stclmfdb-9491
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
A woman guide to breast
|
A woman guide to breast cancer diagnosis and tr
|
/home/sid/tuning/finetune/backend/output/stclmfdb- /home/sid/tuning/finetune/backend/output/stclmfdb-9491/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Document Description
The provided text consists o Document Description
The provided text consists of three distinct resources that collectively cover the spectrum of breast cancer knowledge: the "Breast Cancer and You" (7th Edition) patient handbook by the Canadian Breast Cancer Network (2022), the clinical review "Clinical Diagnosis and Management of Breast Cancer" (2016), and "A Woman’s Guide to Breast Cancer Diagnosis and Treatment" (2000). Together, these documents offer a holistic view of the disease, bridging the gap between patient education and advanced medical practice. The content begins with the biology of the breast, explaining anatomy, the role of hormones, and the lymphatic system, before addressing risk factors, demographics, and common myths. It details the diagnostic journey, covering screening tools like mammography and MRI, the various types of biopsies (needle, core, surgical), and the importance of biomarkers (ER, PR, HER2) and genomic testing in classifying the cancer. The texts extensively review treatment modalities, comparing surgical options (lumpectomy vs. mastectomy, breast conservation techniques), radiation therapy (standard, hypofractionated, and partial breast), and systemic treatments (chemotherapy, endocrine therapy, and targeted therapies). Furthermore, the guides address survivorship issues, including breast reconstruction options, managing side effects like lymphedema, and the emotional aspects of healing. While the older guide provides foundational definitions, the newer resources highlight the shift toward "precision medicine," personalized care plans, and advanced technologies like 3D mammography and radioactive seed localization.
Key Points, Topics, and Headings
1. Anatomy and Risk Factors
Breast Structure: Lobules (milk glands), ducts (tubes), fatty tissue, and lymph nodes (axillary, supraclavicular, internal mammary).
Demographics: Differences in risk and survival among Caucasian, Black/African Canadian, and Ashkenazi Jewish women.
Breast Cancer in Men: Rare (<1%) but requires similar diagnostic and treatment pathways as in women.
Myths vs. Facts: Debunking links between antiperspirants and cancer; understanding family history vs. genetic mutations.
2. Screening and Diagnosis
Screening Tools:
Mammography: Standard 2D vs. Digital Breast Tomosynthesis (3D).
MRI: Recommended for high-risk women or dense breasts.
Biopsy Types:
Fine Needle Aspiration (FNA): Fluid removal.
Core Biopsy: Tissue sample removal.
Surgical Biopsy: Removal of part or all of a lump (incisional vs. excisional).
Localization: Using wires or radioactive seeds to guide surgeons to non-palpable tumors.
Pathology & Staging:
TNM System: Tumor size, Nodal involvement, Metastasis.
Biomarkers: Hormone Receptor status (ER/PR) and HER2 status.
Genomic Assays: Tests like Oncotype DX and MammaPrint to predict recurrence.
3. Treatment Modalities
Surgery:
Lumpectomy (Breast Conservation): Removing the tumor plus a margin; usually followed by radiation.
Mastectomy: Removing breast tissue (Total, Modified Radical, Skin-Sparing, Nipple-Sparing).
Axillary Surgery: Sentinel Lymph Node Biopsy (SLNB) vs. Axillary Lymph Node Dissection (ALND).
Radiation Therapy:
Whole Breast Irradiation (WBI): Standard 5-6 week course.
Hypofractionation: Shorter course (3-4 weeks) with larger doses.
Accelerated Partial Breast Irradiation (APBI): Treating only the tumor bed (1 week).
Medical Oncology:
Chemotherapy: Adjuvant (after surgery) vs. Neoadjuvant (before surgery).
Endocrine Therapy: Tamoxifen and Aromatase Inhibitors for hormone-positive cancers.
Targeted Therapy: HER2-directed agents (e.g., Trastuzumab).
Reconstruction: Imants (saline/silicone) vs. Autologous Flaps (using tissue from back/stomach/buttocks).
4. Support and Survivorship
Lymphedema: Swelling of the arm due to lymph node removal; prevention and management strategies.
Emotional Healing: Dealing with fear, body image, and the benefits of support groups.
Clinical Trials: The opportunity to access new treatments.
Study Questions and Key Points
Biopsy Comparison: What is the main difference between a Fine Needle Aspiration (FNA) and a Core Biopsy?
Key Point: FNA uses a thin needle to extract fluid or cells (often for cysts), while a Core Biopsy uses a larger needle to remove a solid piece of tissue for better pathology analysis.
Staging: What does the "N" stand for in the TNM staging system, and why is it important?
Key Point: "N" stands for Nodes (lymph nodes). It indicates whether cancer has spread to the axillary (armpit) nodes, which is a major factor in determining the need for chemotherapy.
Radiation Advances: How does "Hypofractionation" differ from standard radiation therapy?
Key Point: Hypofractionation delivers a higher dose of radiation per visit over a shorter total time (e.g., 3 weeks instead of 6), offering similar cure rates with greater convenience.
Surgical Precision: What is "Radioactive Seed Localization," and how does it compare to wire localization?
Key Point: It involves implanting a tiny radioactive seed into the tumor to guide the surgeon. It can be more comfortable for the patient than having a wire sticking out of the breast and allows for more flexible surgical scheduling.
Genomic Testing: Why are genomic assays like Oncotype DX used in early-stage breast cancer?
Key Point: These tests analyze the activity of specific genes in the tumor to predict the likelihood of recurrence. This helps doctors decide if a patient will benefit from chemotherapy or if hormone therapy alone is sufficient.
Men’s Breast Cancer: What is the most common type of breast cancer found in men?
Key Point: Invasive ductal carcinoma (starting in the milk ducts).
Easy Explanation: Presentation Outline
Title: Understanding Breast Cancer: From Detection to Recovery
Slide 1: Introduction
Breast cancer is complex, but modern medicine treats it as a highly personalized disease.
We now use "Precision Medicine"—matching the treatment to the specific biology of the tumor.
Slide 2: How is it Found? (Screening)
Mammograms: The standard X-ray screening tool.
3D Mammography (Tomosynthesis): A newer, clearer view that reduces false alarms.
MRI: Used for women with high risk or dense breasts.
Biopsy: If a lump is found, a doctor takes a sample (FNA or Core) to confirm if it is cancer.
Slide 3: Understanding the Diagnosis
Staging: Doctors use the TNM system to describe size and spread.
T: Tumor size.
N: Lymph node status.
M: Metastasis (spread to other organs).
Subtypes: Not all breast cancers are the same.
Hormone Positive: Fueled by estrogen/progesterone.
HER2 Positive: Has too much of a specific protein (aggressive but treatable).
Triple Negative: Lacks all three receptors.
Slide 4: Surgical Options
Lumpectomy: Remove the lump, keep the breast. (Usually requires radiation afterward).
Mastectomy: Remove the entire breast. May be necessary if the tumor is large or widespread.
Lymph Nodes: Doctors usually check the "Sentinel Node" (the first node) to see if cancer has spread.
Reconstruction: Women can choose to rebuild the breast using implants or their own tissue (flaps) immediately or years later.
Slide 5: Radiation Advances
Whole Breast: Treating the entire breast area.
Short Course (Hypofractionation): Same results but fewer visits (e.g., 3 weeks vs. 6 weeks).
Partial Breast (APBI): Treating only the spot where the tumor was, often over just 5 days.
Slide 6: Drug Therapies (Systemic Treatment)
Chemotherapy: Kills fast-growing cells. Can be given before surgery (to shrink the tumor) or after.
Hormone Therapy: Pills (like Tamoxifen) that block hormones. Taken for 5-10 years.
Targeted Therapy: Drugs that specifically attack HER2-positive cells without harming normal cells.
Slide 7: Living Well After Treatment
Lymphedema: Watch for arm swelling; protect the arm from cuts and blood pressure cuffs.
Emotional Support: It is normal to feel fear or anger. Support groups and talking to survivors help.
Follow-up: Regular check-ups and mammograms are essential to monitor for recurrence....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/stclmfdb-9491/data/document.pdf", "num_examples": 9, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/stclmfdb- /home/sid/tuning/finetune/backend/output/stclmfdb-9491/data/stclmfdb-9491.json...
|
null
|
queued
|
1769634417
|
1769644349
|
NULL
|
/home/sid/tuning/finetune/backend/output/stclmfdb- /home/sid/tuning/finetune/backend/output/stclmfdb-9491/adapter...
|
False
|
Edit
Delete
|
|
8f43b997-b048-4598-aa29-40364bb86f1b
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
uvdbjwwt-6683
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
INVASIVE LOBULAR.pdf
|
INVASIVE LOBULAR.pdf
|
/home/sid/tuning/finetune/backend/output/uvdbjwwt- /home/sid/tuning/finetune/backend/output/uvdbjwwt-6683/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Description of the PDF Files
This col 1. Complete Description of the PDF Files
This collection of documents serves as a holistic educational resource on breast health, covering the spectrum from general awareness to specific medical diagnoses. The text explains that breast cancer is a disease characterized by the abnormal growth of cells in breast tissue, affecting both women and men (though more common in women), with statistics showing that 1 in 8 women are at risk. It details the anatomy of the breast, distinguishing between glandular, fibrous, and fatty tissues, and explains how conditions like dense breasts can affect screening. The guides provide in-depth information on various types of breast cancer, including Ductal Carcinoma in Situ (DCIS), Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), and Triple-Negative Breast Cancer (TNBC), outlining their specific symptoms and growth patterns. Furthermore, the documents offer a step-by-step guide to diagnosis, explaining the BI-RADS scoring system for mammograms, the role of biopsies, and the differences between screening and diagnostic tools. Finally, they cover treatment stages (0 to 4), management options (surgery, chemo, radiation), and prevention strategies, while actively debunking common myths about bras, deodorants, and injuries causing cancer.
2. Key Topics & Headings
These are the main headings and topics found across the provided documents:
Overview & Definition of Cancer (Benign vs. Malignant)
Breast Anatomy & Physiology (Ducts, Lobules, Lymphatic System)
Statistics & Demographics (Risk by age, gender, and ethnicity)
Risk Factors (Genetics, Lifestyle, Age, Hormones)
Types of Breast Cancer
Ductal Carcinoma in Situ (DCIS)
Invasive Ductal Carcinoma (IDC)
Invasive Lobular Carcinoma (ILC)
Triple-Negative Breast Cancer (TNBC)
Inflammatory Breast Cancer
Symptoms & Warning Signs (Lumps, Skin changes, Nipple discharge)
Understanding Breast Changes (Benign conditions vs. Precancerous)
Screening & Diagnosis
Self-Examination Techniques
Mammography & BI-RADS Categories
MRI, Ultrasound, and Biopsy methods
Stages of Breast Cancer (Stage 0 to Stage 4)
Treatment Options (Surgery, Chemotherapy, Radiation, Hormone Therapy)
Myths vs. Facts
3. Key Points (Easy Explanation)
Here are the simplified takeaways from the documents:
What is it? Breast cancer happens when cells in the breast grow out of control and form a tumor that can spread to other parts of the body.
Not all lumps are cancer: Many breast changes are benign (not cancer), such as cysts or fibroadenomas. However, any change must be checked by a doctor.
Know your types:
DCIS: Cancer is inside the ducts and hasn't spread (Stage 0).
ILC: Cancer starts in the milk-producing glands (lobules). It can be harder to see on a mammogram than other types.
TNBC: A type of cancer that lacks common receptors, making it harder to treat with standard hormone therapies.
Screening is vital:
Self-Exams: Do them monthly to get to know how your breasts feel.
Mammograms: Women aged 40-75 should get regular scans.
Dense Breasts: Women with dense breasts have higher risk and may need additional screening (like MRI) because mammograms are harder to read on them.
Diagnosis Code (BI-RADS): Mammogram reports use a scale from 0-6.
1-2: Normal/Benign.
3: Probably benign (check in 6 months).
4-5: Suspicious/Highly suggestive of cancer (Biopsy needed).
Treatment: Depends on the stage but often involves surgery (lumpectomy or mastectomy) combined with chemotherapy, radiation, or hormone therapy.
Myths are false: Wearing bras, using deodorant, or getting hit in the chest do not cause breast cancer.
4. Important Questions & Answers
Use these questions to review the comprehensive material:
Q: What is the difference between Ductal Carcinoma in Situ (DCIS) and Invasive Breast Cancer?
A: DCIS is a non-invasive condition where abnormal cells are contained inside the milk ducts and have not spread to surrounding tissue. Invasive breast cancer means the cells have broken through the duct or lobule wall and spread into nearby breast tissue.
Q: Why is Invasive Lobular Carcinoma (ILC) sometimes difficult to diagnose?
A: ILC forms in the lobules and grows in a different pattern than other cancers. It often does not form a distinct lump and can be harder to see on a standard mammogram compared to ductal cancer.
Q: What does "Triple-Negative Breast Cancer" mean?
A: It means the cancer cells test negative for estrogen receptors, progesterone receptors, and HER2 protein. This limits treatment options because hormone therapies are ineffective, so chemotherapy is often required.
Q: What is the BI-RADS category used for in a mammogram report?
A: It is a standardized system to categorize mammogram findings. It helps doctors decide the next steps, such as routine screening (Category 1 or 2), short-term follow-up (Category 3), or biopsy (Category 4 or 5).
Q: Does having dense breast tissue increase the risk of cancer?
A: Yes, women with dense breasts have a slightly higher risk of developing breast cancer. Additionally, dense tissue can hide tumors on a mammogram, making detection more difficult.
5. Presentation Outline
If you are presenting this information, here is a structured outline:
Slide 1: Introduction
Breast Cancer Awareness: Understanding the Disease.
Statistics: 1 in 8 women will be diagnosed; men can get it too.
Slide 2: Anatomy & Types of Cancer
Anatomy: Lobules (milk glands), Ducts (milk passages).
Common Types: DCIS (in ducts), IDC (invasive ductal), ILC (invasive lobular).
Special Types: Triple-Negative (more aggressive, common in younger Black women).
Slide 3: Symptoms & Changes
Warning Signs: Lumps, thickening, nipple discharge, skin dimpling ("orange peel" look).
Benign vs. Malignant: Most lumps are not cancer, but only a doctor can tell.
Note: ILC may not cause a lump, but rather a thickening of the tissue.
Slide 4: Screening & Detection
Tools: Mammogram (standard), Ultrasound, MRI (for dense breasts).
BI-RADS Score: Understanding your report (Categories 0-6).
Biopsy: The only way to definitively diagnose cancer (taking a tissue sample).
Slide 5: Stages of Breast Cancer
Stage 0: Non-invasive (DCIS).
Stage 1 & 2: Early stage, small tumor, limited spread.
Stage 3: Locally advanced (spread to lymph nodes).
Stage 4: Metastatic (spread to bones, liver, lungs, brain).
Slide 6: Treatment Options
Surgery: Lumpectomy (removing lump) vs. Mastectomy (removing breast).
Therapies: Chemotherapy, Radiation, Hormone therapy, Targeted therapy.
Reconstruction: Options available after mastectomy.
Slide 7: Myths vs. Facts
Myth: Deodorants cause cancer. Fact: No evidence.
Myth: A biopsy spreads cancer. Fact: False; it is a safe diagnostic tool.
Myth: Only women get it. Fact: Men get it too, often diagnosed later.
Slide 8: Prevention & Conclusion
Prevention: Healthy weight, exercise, limiting alcohol, breastfeeding, regular screenings.
Takeaway: Early detection saves lives. Know your body and see a doctor for changes....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/uvdbjwwt-6683/data/document.pdf"}...
|
/home/sid/tuning/finetune/backend/output/uvdbjwwt- /home/sid/tuning/finetune/backend/output/uvdbjwwt-6683/data/uvdbjwwt-6683.json...
|
null
|
failed
|
1769634554
|
1769636359
|
NULL
|
/home/sid/tuning/finetune/backend/output/uvdbjwwt- /home/sid/tuning/finetune/backend/output/uvdbjwwt-6683/adapter...
|
False
|
Edit
Delete
|
|
6864b1d9-e97e-4482-8310-fe150649f81a
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
ajwyxbmj-5463
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
breast cancer.pdf
|
breast cancer.pdf
|
/home/sid/tuning/finetune/backend/output/ajwyxbmj- /home/sid/tuning/finetune/backend/output/ajwyxbmj-5463/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Document Description
The provided text is a compr Document Description
The provided text is a comprehensive review article titled "Breast cancer: pathogenesis and treatments," published in Signal Transduction and Targeted Therapy in 2025. This document serves as a high-level scientific update on the current state of breast cancer, integrating epidemiology, molecular biology, and the latest technological advancements. It emphasizes the transition from standard treatment to "precision oncology," where therapies are tailored to the specific genetic and environmental risks of individual patients. The article delves deep into the mechanisms of tumor progression, exploring frontier research areas such as tumor stemness (cells that drive recurrence), cellular senescence (aging cells that may promote cancer), and novel forms of programmed cell death like ferroptosis and cuproptosis. A significant portion of the text is dedicated to the emerging role of Artificial Intelligence (AI) and big data in improving screening accuracy and risk prediction. Additionally, it discusses the impact of the intra-tumoral microbiota (bacteria within tumors) and circadian rhythms on cancer development. Overall, the document provides a panoramic view of breast cancer, linking basic cellular mechanisms to future diagnostic and therapeutic strategies.
Key Points & Main Topics
1. Epidemiology and Risk Factors (Gene-Environment Interaction)
Global Status: Breast cancer accounts for roughly one-third of all malignancies in women.
Genetic vs. Lifestyle: The interplay between genetic predisposition (BRCA mutations, low-penetrance genes) and environmental factors (obesity, alcohol, radiation).
Circadian Rhythms: Disruption of sleep-wake cycles (clock genes) can promote cancer initiation and progression by affecting melatonin and inflammation.
2. The Role of Artificial Intelligence (AI)
Screening: AI algorithms (Deep Learning, CNNs) analyze images to reduce false-positive rates and assist radiologists.
Risk Prediction: AI uses big data to predict individual susceptibility and recommend preventative measures.
Pathology: AI tools (like DeepGrade) analyze digital slides to improve diagnostic accuracy.
3. Molecular Subtypes and Evolution
Classification Evolution: Tracing the history of subtyping from 2000 (gene expression profiles) to 2021 (single-cell methods).
Current Subtypes: Luminal A/B, HER2-enriched, and Triple-Negative Breast Cancer (TNBC).
Refined Classifications: TNBC is further divided into subgroups (e.g., basal-like, mesenchymal, luminal androgen receptor) for better treatment targeting.
4. Mechanisms of Progression (Frontier Research)
Tumor Stemness: Cancer Stem Cells (CSCs) drive metastasis and drug resistance. Markers like CD44 and CD133 are used to identify them.
Cellular Senescence: "Zombie" cells that stop dividing but secrete inflammatory factors (SASP) that can actually help tumors grow and spread.
Novel Programmed Cell Death (PCD):
Ferroptosis: Iron-dependent cell death.
Cuproptosis: Copper-dependent cell death (new concept).
Disulfidptosis: Cell death caused by stress in the actin skeleton due to glucose metabolism issues.
Intra-tumoral Microbiota: Bacteria and fungi found inside tumors can influence how the immune system reacts to the cancer and how effective drugs are.
Immune Reprogramming: How tumors evolve to hide from the immune system (e.g., using checkpoints like PD-L1).
5. Emerging Diagnostics and Treatment
Liquid Biopsy: Using blood samples to find circulating tumor DNA (ctDNA) for early detection.
Precision Medicine: Targeting specific pathways (PI3K/AKT/mTOR) and using specific inhibitors (CDK4/6 inhibitors) based on tumor genetics.
Study Questions
AI Application: How is Artificial Intelligence currently being used to improve breast cancer screening?
Key Point: AI uses deep learning models to analyze mammograms or pathology slides, helping to reduce false positives, detect cancer earlier, and predict individual risk.
Novel Cell Death: What is "Cuproptosis," and how does it differ from apoptosis?
Key Point: Cuproptosis is a newly discovered form of regulated cell death caused by excessive copper accumulation leading to mitochondrial stress, distinct from the traditional programmed cell death (apoptosis).
Tumor Stemness: Why are Cancer Stem Cells (CSCs) considered a major challenge in treatment?
Key Point: CSCs have the ability to self-renew and differentiate, driving tumor initiation, metastasis, and resistance to chemotherapy and radiation.
Senescence: What is the "Senescence-Associated Secretory Phenotype" (SASP)?
Key Point: It is a condition where senescent (aged) cells secrete inflammatory factors and cytokines that can paradoxically promote tumor growth and immune evasion.
Microbiota: What is the "intra-tumoral microbiota," and why is it significant?
Key Point: It refers to the community of bacteria and fungi living within the tumor tissue. It is significant because it can modulate the tumor microenvironment, affecting drug efficacy and anti-tumor immunity.
Subtypes: How has the molecular classification of Triple-Negative Breast Cancer (TNBC) changed recently?
Key Point: TNBC is no longer viewed as a single disease but is now stratified into distinct subtypes (e.g., basal-like, mesenchymal, luminal androgen receptor) to allow for more precise, subtype-specific treatments.
Easy Explanation & Presentation Outline
Title: The Future of Breast Cancer: AI, Stem Cells, and New Ways to Kill Cancer
Slide 1: Introduction – Precision Oncology
Concept: Moving away from "one size fits all" treatment.
Goal: Treat breast cancer based on the patient's specific genes, environment, and tumor biology.
Focus: Using technology (AI) and understanding deep biology (stemness, microbiota).
Slide 2: Artificial Intelligence (AI) in the Clinic
The Problem: Doctors sometimes miss things or see "false alarms" in mammograms.
The AI Solution: Computer algorithms (Deep Learning) scan X-rays to spot patterns humans might miss.
Benefit: Earlier detection and less unnecessary stress for patients.
Slide 3: The Roots of Cancer (Stemness)
The Idea: Tumors contain "leader" cells called Cancer Stem Cells (CSCs).
Why they matter: These cells are stubborn. They survive chemotherapy and cause the cancer to come back (recur) later.
Research Focus: Finding drugs to specifically target these "leader" cells.
Slide 4: "Zombie" Cells and Inflammation (Senescence)
Senescence: When cells get old or damaged, they stop dividing.
The Twist: These "zombie" cells don't die. They release chemicals (SASP) that cause inflammation.
The Risk: This inflammation can actually help nearby cancer cells grow and spread.
Slide 5: New Ways to Kill Cancer Cells
Beyond Chemotherapy: We are discovering new "switches" to trigger cell death.
Ferroptosis: Killing cells by messing with their iron metabolism.
Cuproptosis: Killing cells by overloading them with copper.
Why it helps: These methods can kill cancer cells that have become resistant to traditional drugs.
Slide 6: Tiny Helpers (Microbiota)
Discovery: Bacteria live inside breast tumors.
Function: They aren't just passengers; they talk to the immune system and affect how drugs work.
Future: Maybe we can modify these bacteria to help treatment work better.
Slide 7: Lifestyle and Circadian Rhythms
Sleep Matters: Disrupting your body clock (night shifts, poor sleep) disrupts "clock genes."
The Link: This disruption can directly promote cancer growth by lowering melatonin and increasing inflammation.
Slide 8: Conclusion
Summary: Breast cancer treatment is getting smarter.
The Future: A mix of high-tech AI, deep biological research (stem cells/microbiome), and personalized medicine.
Takeaway: Understanding the mechanism of the disease leads to better cures....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/ajwyxbmj-5463/data/document.pdf", "num_examples": 285, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/ajwyxbmj- /home/sid/tuning/finetune/backend/output/ajwyxbmj-5463/data/ajwyxbmj-5463.json...
|
null
|
queued
|
1769634618
|
1769657778
|
NULL
|
/home/sid/tuning/finetune/backend/output/ajwyxbmj- /home/sid/tuning/finetune/backend/output/ajwyxbmj-5463/adapter...
|
False
|
Edit
Delete
|
|
c01f4120-0cab-437f-9012-efae122e90ac
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
dohqoily-0601
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Understanding Breast c
|
Understanding Breast cancer.pdf
|
/home/sid/tuning/finetune/backend/output/dohqoily- /home/sid/tuning/finetune/backend/output/dohqoily-0601/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Description of the PDF File
This coll 1. Complete Description of the PDF File
This collection of documents serves as an all-encompassing educational guide covering the medical and practical aspects of breast cancer. It begins with fundamental definitions, explaining breast anatomy—including lobules, ducts, and lymph nodes—and defines cancer as the uncontrollable growth of abnormal cells that may form benign or malignant tumors. The text provides detailed statistics, noting that 1 in 8 women are at risk, and categorizes breast cancer into various types such as Ductal Carcinoma in Situ (DCIS), Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), and Triple-Negative Breast Cancer (TNBC). It offers comprehensive guidance on risk factors ranging from genetics (BRCA genes) to lifestyle choices, and outlines symptoms ranging from lumps to skin changes. Furthermore, the documents explain the diagnostic process in depth, detailing the differences between screening and diagnostic mammograms, the BI-RADS scoring system, the role of MRI and ultrasound, and biopsy procedures. It also covers staging (Stage 0 to 4), grading, and specific biomarkers (ER, PR, HER2) that dictate treatment. Finally, it lists treatment options including surgery, chemotherapy, radiation, and hormone therapy, while debunking common myths and providing advice on prevention and follow-up care.
2. Key Topics & Headings
These are the main headings and topics found throughout the combined documents:
Breast Anatomy & Physiology (Lobules, Ducts, Lymphatic System)
Definition of Cancer (Benign vs. Malignant, In situ vs. Invasive)
Statistics & Demographics (Risk by age, gender, and ethnicity)
Types of Breast Cancer
Ductal Carcinoma in Situ (DCIS)
Invasive Ductal Carcinoma (IDC)
Invasive Lobular Carcinoma (ILC)
Triple-Negative Breast Cancer (TNBC)
Inflammatory Breast Cancer
Risk Factors (Genetics, Age, Hormones, Lifestyle, Dense Breasts)
Symptoms & Warning Signs
Screening & Detection
Self-Examination
Mammography (2D vs. 3D/Tomosynthesis)
Breast MRI & Ultrasound
Diagnostic Procedures
Biopsy Types (Needle, Core, Surgical)
BI-RADS Assessment Categories
Staging & Grading (TNM System, Stage 0–4)
Biomarkers (ER, PR, HER2 Status)
Treatment Options
Surgery (Lumpectomy vs. Mastectomy)
Radiation Therapy
Chemotherapy & Targeted Therapy
Hormone Therapy
Side Effects & Recovery (Lymphoedema, Reconstruction)
Myths vs. Facts
3. Key Points (Easy Explanation)
Here are the simplified takeaways from the documents:
Anatomy: Breasts are made of glands (lobules that make milk), tubes (ducts that carry milk), and lymph nodes (which help fight infection).
Types:
DCIS: Cancer cells are inside the ducts and haven't spread (Stage 0).
IDC: The most common type; cancer starts in ducts and invades nearby tissue.
ILC: Starts in the milk glands (lobules). It is harder to feel as a distinct lump and harder to see on a mammogram than IDC.
TNBC: A type that lacks estrogen, progesterone, and HER2 receptors. It is often treated with chemotherapy.
Screening:
Self-Exam: Know your breasts so you can spot changes.
Mammogram: The standard X-ray screening tool.
BI-RADS Score: A report code from 0 to 6. Scores of 4 or 5 usually mean a biopsy is needed.
Diagnosis: Doctors use a "Triple Test": Physical exam, Imaging (Mammogram/Ultrasound), and Biopsy (taking tissue samples).
Biomarkers: Doctors test for ER/PR (hormone receptors) and HER2. This tells them if hormone therapy or targeted drugs will work.
Treatment:
Lumpectomy: Remove the lump but keep the breast.
Mastectomy: Remove the whole breast.
Adjuvant: Treatment given after surgery to kill remaining cells.
Neoadjuvant: Treatment given before surgery to shrink the tumor.
Myths: Bras, deodorants, and injuries do not cause cancer.
4. Important Questions & Answers
Use these questions to review the comprehensive material:
Q: What is the difference between Ductal Carcinoma in Situ (DCIS) and Invasive Cancer?
A: DCIS is a non-invasive cancer where abnormal cells are contained within the milk ducts. Invasive cancer (like IDC or ILC) means the cells have broken through the duct or lobule wall and spread into surrounding fatty tissue of the breast.
Q: Why is Invasive Lobular Carcinoma (ILC) difficult to detect?
A: ILC grows in a linear pattern rather than a distinct lump. It often does not show up clearly on mammograms and may be better detected via MRI or ultrasound.
Q: What does "Triple-Negative Breast Cancer" mean?
A: It means the cancer cells test negative for estrogen receptors, progesterone receptors, and HER2 protein. These cancers do not respond to hormone therapies and are usually treated with chemotherapy.
Q: What are the BI-RADS categories used in mammogram reports?
A: They range from 0 to 6.
0: Incomplete, need more imaging.
1-2: Negative or Benign (routine screening).
3: Probably benign (short-term follow-up).
4-5: Suspicious or Highly suggestive of malignancy (biopsy recommended).
6: Known biopsy-proven cancer.
Q: What is the difference between a "lumpectomy" and a "mastectomy"?
A: A lumpectomy (breast-conserving surgery) removes only the tumor and a margin of healthy tissue. A mastectomy removes the entire breast tissue.
5. Presentation Outline
If you are presenting this information, here is a structured outline:
Slide 1: Introduction
Understanding Breast Cancer: Anatomy, Types, and Treatment.
Goal: Awareness, Early Detection, and Myth Busting.
Slide 2: Breast Anatomy & Cancer Basics
Anatomy: Lobules (glands), Ducts (tubes), Lymph Nodes (filters).
Cancer: Uncontrolled cell growth.
Benign vs. Malignant: Non-spreading vs. spreading.
Slide 3: Common Types of Breast Cancer
DCIS: Non-invasive, contained in ducts (Stage 0).
IDC: Most common, invasive ductal cancer (~80% of cases).
ILC: Invasive lobular cancer; harder to detect on mammograms.
TNBC: Aggressive, lacks common receptors; requires chemotherapy.
Slide 4: Risk Factors & Symptoms
Risks: Age, Gender, Genetics (BRCA), Dense Breasts, Lifestyle (Alcohol/Weight).
Symptoms: Lump, thickening, nipple discharge, skin dimpling, change in size/shape.
Slide 5: Screening & Diagnosis
Mammogram: Standard screening tool (Gold standard).
Additional Tests: Ultrasound (sound waves), MRI (magnets/contrasts).
Biopsy: The only definitive way to diagnose (Fine Needle, Core, Surgical).
BI-RADS: Understanding the 0-6 scale on your report.
Slide 6: Staging & Biomarkers
Staging: Size (T), Nodes (N), Metastasis (M). Stages 0 through 4.
Receptor Status: ER+, PR+ (Hormone therapy); HER2+ (Targeted therapy); Triple Negative (Chemo).
Slide 7: Treatment Pathways
Surgery: Lumpectomy vs. Mastectomy (+ Reconstruction).
Radiation: High-energy rays to kill cells (often after lumpectomy).
Systemic Therapy: Chemotherapy (kill fast-growing cells), Hormone Therapy (block estrogen), Targeted Therapy (attack specific proteins).
Slide 8: Myths vs. Facts
Myth: Deodorants/Coffee cause cancer. Fact: No evidence.
Myth: A biopsy spreads cancer. Fact: Safe and necessary procedure.
Myth: Only women get breast cancer. Fact: Men can get it too (rare but possible).
Slide 9: Prevention & Conclusion
Prevention: Healthy weight, exercise, limit alcohol, breastfeeding.
Conclusion: Early detection is key. Know your normal, report changes immediately....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/dohqoily-0601/data/document.pdf", "num_examples": 28, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/dohqoily- /home/sid/tuning/finetune/backend/output/dohqoily-0601/data/dohqoily-0601.json...
|
null
|
queued
|
1769634680
|
1769648218
|
NULL
|
/home/sid/tuning/finetune/backend/output/dohqoily- /home/sid/tuning/finetune/backend/output/dohqoily-0601/adapter...
|
False
|
Edit
Delete
|
|
2646fbe3-4403-44d4-95fe-08232c1701ac
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
rktdjjhe-7556
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Understanding Breast canc
|
Understanding Breast cancer.pdf
|
/home/sid/tuning/finetune/backend/output/rktdjjhe- /home/sid/tuning/finetune/backend/output/rktdjjhe-7556/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Paragraph Description
This document i 1. Complete Paragraph Description
This document is an excerpt from "Understanding Breast Cancer," a patient guide published by Cancer Council Australia in September 2024. Designed to support individuals diagnosed with breast cancer, as well as their families and friends, the booklet provides a thorough overview of the disease, covering the biology of cancer, the anatomy of the breast, and risk factors. It details the diagnostic process, including imaging tests like mammograms and ultrasounds, biopsies, and the staging/grading of cancer. The text explains complex pathology results such as hormone receptor status, HER2 status, and triple-negative breast cancer, offering insight into how these factors influence treatment decisions. Furthermore, it outlines treatment options ranging from breast-conserving surgery and mastectomy to reconstruction, while emphasizing the importance of multidisciplinary care, emotional support, and making informed decisions through resources like second opinions and clinical trials.
2. Topics, Headings, and Key Points
What is Cancer?
Definition: A disease where abnormal cells grow uncontrollably.
Malignant vs. Benign: Malignant tumors can spread to other parts of the body (metastasis); benign tumors do not.
Primary vs. Secondary: The original cancer is primary; if it spreads, the new tumors are secondary or metastases.
The Breasts & Anatomy
Structure: Made up of lobes (milk-producing sections), lobules (glands), ducts (tubes carrying milk), and fatty/fibrous tissue.
Lymphatic System: A network of vessels and nodes (glands). The first place breast cancer usually spreads is to the lymph nodes in the armpit (axilla).
Key Facts & Risk Factors
Prevalence: About 20,700 people diagnosed annually in Australia; 1 in 8 women by age 85.
Risk Factors: Being female, aging, family history (gene mutations like BRCA1/2), lifestyle factors (alcohol, weight, smoking), and hormonal factors.
Symptoms: Lumps, changes in size/shape, skin dimpling, nipple changes (inversion, discharge), or pain.
Diagnosis & Testing
Triple Test: Physical examination, imaging (mammogram, ultrasound, MRI), and biopsy.
Biopsy Types: Fine needle aspiration (FNA), core biopsy, vacuum-assisted, or surgical biopsy.
Staging: The TNM system (Tumour size, Node involvement, Metastasis).
Early (Stage 1-2): Contained in breast/armpit.
Locally Advanced (Stage 3): Larger or spread to skin/chest muscle.
Metastatic (Stage 4): Spread to distant body parts.
Grading: How fast the cancer is growing (Grade 1 = slow, Grade 3 = fast).
Understanding Tumour Biology
Hormone Receptors: ER+ (Oestrogen) and PR+ (Progesterone). These cancers respond to hormone therapy.
HER2 Status: A protein that helps cancer grow. HER2+ cancers respond to targeted therapies.
Triple Negative: Lacks ER, PR, and HER2. Treated mainly with chemotherapy and immunotherapy.
Treatment Planning
Multidisciplinary Team (MDT): A group of specialists (surgeons, oncologists, nurses) who plan care together.
Decision Making: Involves understanding prognosis, considering second opinions, and discussing clinical trials.
Surgical Treatments
Breast-Conserving Surgery (Lumpectomy): Removes the tumor and some healthy tissue; usually followed by radiation.
Mastectomy: Removes the whole breast. May be single or bilateral (both).
Reconstruction: Creating a new breast shape using implants or own tissue, done at the same time or later.
Axillary Surgery: Removal of lymph nodes to check for cancer spread.
3. Easy Explanation (Plain English)
What is Breast Cancer?
Imagine your body is like a busy city with buildings (cells) that are constantly being built and torn down. Usually, this happens in an orderly way. Breast cancer happens when some cells stop following the rules and start building out of control, forming a lump (tumor). These "bad cells" can break away and travel to other parts of the city (body), which doctors call metastasis.
How do doctors find it?
Doctors use three main methods to check for breast cancer:
Feeling: The doctor physically checks the breasts and armpits for lumps.
Pictures: They use X-rays (mammograms) or soundwaves (ultrasound) to look inside the breast.
Sampling: If they see something suspicious, they take a tiny piece of tissue (a biopsy) to look at under a microscope.
What do the test results mean?
Doctors look for specific "locks" on the cancer cells to decide which medicine (key) will work best:
Hormone Receptors (ER/PR): If the cancer uses hormones to grow, doctors give drugs to block those hormones.
HER2: If the cancer has too much of a specific protein, doctors use targeted drugs to attack it.
Triple Negative: If the cancer has none of these, doctors use strong drugs (chemotherapy) to kill the cells.
What is the treatment?
Surgery: You can either have just the lump removed (keeping the breast) or the whole breast removed. You can also choose to have the breast rebuilt (reconstruction) afterward.
Other Treatments: Sometimes, doctors give medicine before surgery to shrink the tumor (neoadjuvant) so the surgery is easier. Other times, they give medicine after surgery (adjuvant) to kill any leftover cells.
4. Presentation Slides Outline
Slide 1: Title
Understanding Breast Cancer
A Guide for Patients, Families, and Friends
Source: Cancer Council Australia (Sep 2024)
Slide 2: What is Breast Cancer?
The Basics: Abnormal growth of cells in the breast tissue.
Invasive: Cancer has spread from the ducts/lobules into surrounding tissue.
Metastatic (Advanced): Cancer has spread to distant parts of the body (e.g., bones, liver).
Anatomy: Starts in ducts (80%) or lobules.
Slide 3: Risk Factors & Symptoms
Who is at risk?
Primarily women (99% of cases), but men can get it too.
Risk increases with age (especially over 50).
Family history (BRCA1/2 genes) and lifestyle factors (alcohol, weight).
Warning Signs:
New lumps or thickening.
Change in size/shape.
Nipple changes (inversion, discharge, crusting).
Skin dimpling or redness.
Slide 4: Diagnosis Process
Step 1: Imaging
Mammogram: Low-dose X-ray (screening/diagnostic).
Ultrasound: Soundwaves (good for younger/dense breasts).
MRI: For high-risk patients or complex cases.
Step 2: Biopsy
Taking a tissue sample (Core needle, FNA, or Surgical).
Only way to confirm cancer.
Step 3: Staging & Grading
Determining how far it has spread (Stage 1-4) and how fast it grows (Grade 1-3).
Slide 5: Understanding Your Results (Pathology)
Hormone Receptors (ER/PR):
Positive (+): Cancer feeds on hormones. Treatment: Hormone Therapy.
Negative (-): Does not feed on hormones.
HER2 Status:
Positive (+): Too much HER2 protein. Treatment: Targeted Therapy.
Triple Negative:
ER-, PR-, HER2-.
Treatment: Chemotherapy and Immunotherapy.
Slide 6: Treatment Options
Surgery:
Breast-Conserving (Lumpectomy): Remove lump + margin. Usually needs radiation.
Mastectomy: Remove whole breast. Option for immediate reconstruction.
Therapy Sequence:
Neoadjuvant: Treatment before surgery to shrink tumor.
Adjuvant: Treatment after surgery to kill remaining cells.
Other Therapies:
Radiation Therapy, Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy.
Slide 7: Making Decisions & Support
Multidisciplinary Team (MDT): Specialists working together for your care.
Your Rights: Ask for a second opinion; join clinical trials.
Support:
Call Cancer Council 13 11 20.
Access nurses, counselors, and support groups....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/rktdjjhe-7556/data/document.pdf", "num_examples": 522, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/rktdjjhe- /home/sid/tuning/finetune/backend/output/rktdjjhe-7556/data/rktdjjhe-7556.json...
|
null
|
queued
|
1769685019
|
1769694641
|
NULL
|
/home/sid/tuning/finetune/backend/output/rktdjjhe- /home/sid/tuning/finetune/backend/output/rktdjjhe-7556/adapter...
|
False
|
Edit
Delete
|
|
ae8f9a4e-a472-4d9b-a594-5c487b6a52d5
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
hqpqqhxl-1694
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Breast Cancer Treatment
|
Breast Cancer Treatment.pdf
|
/home/sid/tuning/finetune/backend/output/hqpqqhxl- /home/sid/tuning/finetune/backend/output/hqpqqhxl-1694/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Paragraph Description
The provided do 1. Complete Paragraph Description
The provided documents offer a dual perspective on breast cancer, combining patient-focused education with clinical practice guidelines. The first text, "Understanding Breast Cancer" (Cancer Council Australia, 2024), serves as a comprehensive guide for patients and families, explaining the biology of the disease, the anatomy of the breast, and the emotional impact of a diagnosis. It details the diagnostic "triple test," breaks down complex pathology results like hormone receptor and HER2 status, and outlines treatment pathways including surgery, reconstruction, and adjuvant therapies. The second text, a clinical article from American Family Physician (2021), targets healthcare providers and focuses on the medical management of the disease. It covers epidemiology, validated risk assessment tools, and pharmacological risk reduction strategies (such as tamoxifen or aromatase inhibitors). Furthermore, it provides detailed staging criteria for non-invasive (DCIS) and invasive cancers, outlines specific systemic therapies (chemotherapy, endocrine, immunotherapy), and discusses the management of recurrent and metastatic disease. Together, these resources provide a holistic view of breast cancer care, from initial screening and prevention to advanced treatment and survivorship.
2. Key Points, Headings, and Topics
Introduction & Epidemiology
Prevalence: Breast cancer is the second most common cancer in women (after skin cancer) and a leading cause of cancer death.
Risk Factors: Aging, female sex, family history (BRCA1/2 mutations), dense breast tissue, hormonal factors (early menarche, late menopause), and lifestyle (alcohol, obesity).
Risk Reduction: High-risk patients may use chemoprevention (e.g., tamoxifen, raloxifene) or undergo bilateral risk-reducing mastectomy.
Anatomy & Pathology
Anatomy: Breasts contain lobules (glands), ducts (tubes), and stroma (fatty tissue). Cancer usually starts in ducts (80%) or lobules.
DCIS (Stage 0): Ductal Carcinoma in Situ is non-invasive but can progress. Treated with lumpectomy + radiation or mastectomy.
Tumor Subtypes:
Hormone Receptor Positive (ER+/PR+): Fueled by estrogen/progesterone.
HER2 Positive (ERBB2): Overexpression of the HER2 protein; aggressive but treatable with targeted therapy.
Triple Negative: Lacks all three receptors; treated primarily with chemotherapy and immunotherapy.
Diagnosis & Staging
The Triple Test: Physical exam, Imaging (Mammogram, Ultrasound, MRI), and Biopsy.
Biopsy Types: Fine needle aspiration, core needle biopsy, and surgical biopsy.
Staging System (TNM):
Stage 0: DCIS (Non-invasive).
Stage I-II: Early invasive (confined to breast/nearby nodes).
Stage III: Locally advanced (large tumor or significant lymph node involvement).
Stage IV: Metastatic (spread to distant organs like bone, liver, lung).
Treatment Modalities
Surgery:
Lumpectomy (Breast-conserving): Removal of tumor + margins; usually requires radiation.
Mastectomy: Removal of the entire breast.
Lymph Node Surgery: Sentinel lymph node biopsy (preferred for early stages) vs. Axillary lymph node dissection (for involved nodes).
Radiation Therapy: Used after lumpectomy or for high-risk mastectomy patients to kill remaining cells.
Systemic Therapies:
Neoadjuvant: Given before surgery to shrink tumors (common in HER2+ or Triple Negative).
Adjuvant: Given after surgery to prevent recurrence.
Pharmacology:
Endocrine Therapy: Tamoxifen (premenopausal) or Aromatase Inhibitors (postmenopausal) for ER+ cancers.
Targeted Therapy: Monoclonal antibodies (Trastuzumab, Pertuzumab) for HER2+ cancers.
Chemotherapy: Anthracyclines and Taxanes; essential for Triple Negative breast cancer.
Bone Modifiers: Bisphosphonates or Denosumab to protect bone health during treatment and prevent metastasis.
Advanced & Recurrent Disease
Metastatic (Stage IV): Treatable but generally not curable. Focus is on symptom management, extending life, and quality of life.
Recurrence: Local recurrence may require surgery; distant recurrence is treated as Stage IV.
3. Questions to Consider (Review/Discussion)
Screening: What are the three components of the "triple test" used to diagnose breast cancer?
Staging: What is the difference between Stage 0 (DCIS) and Stage I breast cancer in terms of invasiveness?
Biology: How does the status of Estrogen Receptors (ER), Progesterone Receptors (PR), and HER2 dictate the treatment plan?
Surgery: Under what circumstances is a mastectomy recommended over a lumpectomy?
Pharmacology: Why are bisphosphonates recommended for postmenopausal women undergoing aromatase inhibitor therapy?
Advanced Disease: What are the primary treatment goals for Stage IV (metastatic) breast cancer?
4. Easy Explanation (Simplified Summary)
What is it?
Breast cancer happens when cells in the breast grow out of control and form a lump. Usually, it starts in the tubes (ducts) that carry milk or in the milk-producing glands (lobules).
How do we find it?
Doctors feel for lumps and take pictures of the breast using X-rays (mammograms) or soundwaves (ultrasound). If they see a spot, they stick a small needle into it to take a sample (biopsy) and check it under a microscope.
What determines the treatment?
Not all breast cancers are the same. Doctors look for "locks" on the cancer cells:
Hormone Locks (ER/PR): If the cancer uses hormones to grow, we give pills to block those hormones.
HER2 Locks: If the cancer has too much of a specific protein, we use targeted drugs to attack it.
No Locks (Triple Negative): We use strong drugs (chemotherapy) to kill the cells.
How do we treat it?
Surgery: We can either remove just the lump (lumpectomy) or the whole breast (mastectomy).
Radiation: High-energy beams used after lumpectomy to zap any leftover cells.
Medicine:
Before surgery (Neoadjuvant): To shrink big tumors.
After surgery (Adjuvant): To make sure the cancer doesn't come back.
What about advanced cancer?
If the cancer spreads to other parts of the body (like bones or liver), it is called Stage IV. It can't be cured completely, but treatments can help control it, shrink tumors, and help the patient live longer and feel better.
5. Presentation Outline
Slide 1: Title
Breast Cancer: From Diagnosis to Treatment
Integrating Patient Care & Clinical Guidelines
Slide 2: The Basics & Risk Factors
What is it? Uncontrolled cell growth in breast ducts or lobules.
Who is at risk?
Women (primary), Men (rare).
Age, Family history (BRCA1/2), Genetics.
Prevention:
Lifestyle (limit alcohol, exercise).
Chemoprevention (Tamoxifen/Raloxifene) for high-risk groups.
Slide 3: Diagnosis & Staging
Detection Methods:
Clinical Exam & Mammography (Screening).
Ultrasound & MRI (Diagnostic tools).
Biopsy (Confirmation).
Staging the Cancer:
Stage 0 (DCIS): Non-invasive (confined to ducts).
Stage I-III: Varying sizes and lymph node involvement (Localized/Locally Advanced).
Stage IV: Metastatic (Spread to distant organs).
Slide 4: Tumor Subtypes (Biology Matters)
Hormone Receptor Positive (ER+/PR+):
Treatment: Hormone therapy (Tamoxifen, Aromatase Inhibitors).
HER2 Positive (ERBB2+):
Treatment: Targeted therapy (Trastuzumab/Herceptin) + Chemotherapy.
Triple Negative:
No receptors present.
Treatment: Chemotherapy & Immunotherapy.
Slide 5: Surgical Interventions
Breast-Conserving (Lumpectomy):
Remove tumor + clear margins.
Follow-up: Radiation therapy is standard.
Mastectomy:
Removal of entire breast.
Follow-up: Radiation only for high-risk cases.
Lymph Nodes:
Sentinel Node Biopsy (Checks first few nodes).
Axillary Dissection (Removes many nodes if cancer is present).
Slide 6: Medical Therapies (Systemic Treatment)
Chemotherapy: Kills fast-growing cells. Used before (neoadjuvant) or after (adjuvant) surgery. Key for Triple Negative.
Endocrine Therapy: Blocks hormones. Duration: 5–10 years.
Targeted Therapy: Attacks specific cancer cell features (e.g., Trastuzumab for HER2).
Bone Health: Bisphosphonates (e.g., Zoledronic acid) to prevent bone loss and metastasis.
Slide 7: Advanced & Recurrent Disease
Recurrence:
Local: Often treated with surgery/mastectomy.
Distant: Treated as metastatic disease.
Metastatic (Stage IV):
Goal: Palliative (Quality of life, symptom control).
Treatments: Continuous systemic therapy (Hormone, Chemo, Targeted) tailored to subtype.
Slide 8: Summary & Support
Multidisciplinary care is essential (Surgeons, Oncologists, Nurses).
Patient involvement in decision-making (Clinical trials, second opinions).
Support resources: Cancer Council, Family support, Psychological counseling....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/hqpqqhxl-1694/data/document.pdf", "num_examples": 134, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/hqpqqhxl- /home/sid/tuning/finetune/backend/output/hqpqqhxl-1694/data/hqpqqhxl-1694.json...
|
null
|
queued
|
1769685387
|
1769688667
|
NULL
|
/home/sid/tuning/finetune/backend/output/hqpqqhxl- /home/sid/tuning/finetune/backend/output/hqpqqhxl-1694/adapter...
|
False
|
Edit
Delete
|
|
523dee20-26ec-4cca-a489-e5e9dc959fa5
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
fzzonqbc-9351
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Breast_Cancer_Informat
|
Breast_Cancer_Information_Sheet.pdf
|
/home/sid/tuning/finetune/backend/output/fzzonqbc- /home/sid/tuning/finetune/backend/output/fzzonqbc-9351/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Description of the PDF File
The document is a U.S Description of the PDF File
The document is a U.S. Citizenship and Immigration Services (USCIS) Form I-693, titled "Report of Immigration Medical Examination and Vaccination Record," specifically the edition dated 01/20/25. This official form is used by individuals applying for adjustment of status or certain immigration benefits within the United States to prove they are free of health-related conditions that would make them inadmissible to the country. The form is a collaborative document divided into 11 parts, ranging from basic biographical information provided by the applicant to complex medical evaluations performed by a designated civil surgeon. It includes sections for recording the results of required medical tests for communicable diseases like tuberculosis, syphilis, and gonorrhea, as well as a screening for physical or mental disorders and drug abuse. A significant portion of the form is dedicated to the vaccination record, where the civil surgeon verifies that the applicant has received all immunizations required by CDC guidelines. The document concludes with strict certification sections where the applicant, interpreter, preparer, and civil surgeon must all sign under penalty of perjury to attest that the information provided is true and complete.
Key Points, Headings, and Topics
1. Form Overview & Administration
Form Number: I-693
Agency: Department of Homeland Security / U.S. Citizenship and Immigration Services (USCIS).
Expiration Date: 09/30/2027.
Edition: 01/20/25.
2. Structural Breakdown by Part
Part 1: Information About You
Filled out by the applicant.
Collects basic data: Name, Address, A-Number, Date of Birth, Country of Birth.
Part 2: Applicant's Statement
Contact info (Phone, Email).
Certification and Signature (Crucial: Must not sign until instructed by the civil surgeon).
Part 3: Interpreter's Information
Required only if an interpreter was used.
Includes contact info and a certification of fluency.
Part 4: Preparer's Information
Filled out only if someone other than the applicant prepared the form (e.g., a lawyer or family member).
Part 5: Applicant's Identification
Completed by the Civil Surgeon.
Records the ID document used (e.g., Passport) to verify the applicant's identity.
Part 6: Summary of Medical Examination
A high-level summary by the doctor.
Checks boxes for "Class A" conditions (serious/public health risk) or "Class B" conditions (less serious).
Part 7: Civil Surgeon's Contact Info & Certification
Doctor's name, address, and license details.
Includes the Civil Surgeon ID (CSID).
Stamps the official seal of the practice.
Part 8: Civil Surgeon Worksheet (The Medical Details)
Tuberculosis (TB): IGRA blood test results, Chest X-ray findings, and Sputum culture results.
Syphilis: Serologic test results (Nontreponemal and Treponemal).
Gonorrhea: Nucleic Acid Amplification Test (NAAT) results.
Physical/Mental Disorders: Screening for harmful behavior associated with disorders.
Drug Abuse/Addiction: Screening for substance use disorders involving controlled substances.
Part 9: Referral Evaluation
Used if the applicant is sent to a specialist or health department for further treatment (e.g., for TB).
Part 10: Vaccination Record
A grid of vaccines (MMR, Tetanus, Hepatitis B, Varicella, COVID-19, Influenza, etc.).
Columns for dates received, transfer of records, and waivers (contraindication, not appropriate, etc.).
Part 11: Additional Information
Blank space for extra notes if the other sections run out of room.
3. Key Medical Definitions
Class A Condition: A medical condition that prohibits entry into the U.S. (e.g., active TB, untreated syphilis, dangerous mental disorder with harmful behavior).
Class B Condition: A physical or mental abnormality, disease, or disability that is serious but permanent in nature or lacks a current harmful behavior (e.g., old scar tissue on lungs, well-controlled mental health condition).
Topics & Questions for Review
Topic: Applicant Responsibilities
Question: Who is responsible for completing Part 1 of Form I-693?
Answer: The applicant (the person requesting the medical examination).
Question: Should the applicant sign the form before seeing the doctor?
Answer: No. The note specifically states, "Do not sign or date Form I-693 until instructed to do so by the civil surgeon."
Topic: Medical Screening
Question: What is the initial screening test required for Tuberculosis for applicants 2 years and older?
Answer: An Interferon Gamma Release Assay (IGRA), such as QuantiFERON or T-Spot.
Question: For which age groups is the Gonorrhea test required?
Answer: Applicants 18 to 24 years of age.
Topic: Vaccination
Question: Where should specific vaccine details for COVID-19 be written?
Answer: In the "Remarks" section, writing "COVID-19" and specifying the vaccine brand.
Question: What are the three types of "Blanket Waivers" a civil surgeon might request?
Answer: Not Medically Appropriate, Contraindication, or Insufficient Time Interval.
Topic: Certifications
Question: Under what penalty do the applicant, interpreter, preparer, and civil surgeon sign the form?
Answer: Under penalty of perjury (meaning they swear the information is true and correct, with legal consequences for lying).
Easy Explanation (Plain English)
What is this document?
Think of Form I-693 as a "Health Report Card" for the U.S. government. When someone wants to live in the U.S. permanently (get a Green Card), the government needs to make sure they aren't bringing in dangerous diseases and that they have had their shots.
How does it work?
The Applicant: You fill out the first part with your name, address, and ID numbers.
The Doctor (Civil Surgeon): You take this form to a special doctor approved by immigration. They check your eyes, ears, heart, and lungs. They also take a blood test to check for things like TB and Syphilis.
The Shots: The doctor looks at your shot record. If you are missing shots (like the Measles or Flu shot), you might need to get them.
The Results:
If you are healthy, the doctor checks a box saying you have no "Class A" conditions (bad diseases).
If you have a sickness that needs treatment, the doctor notes it as a "Class B" condition.
The Signatures: You sign the paper to say this is really you. The doctor signs it to say they actually checked you.
Submission: You give this sealed envelope to the immigration office (USCIS) to prove you are healthy enough to enter or stay in the country.
Presentation Outline
Slide 1: Title Slide
Title: Understanding Form I-693
Subtitle: Report of Immigration Medical Examination and Vaccination Record
Date: Edition 01/20/25
Slide 2: What is Form I-693?
Purpose: Required for immigration benefits (Green Card applicants).
Goal: Ensure the applicant does not have a health condition that would make them inadmissible to the U.S.
Key Players: Applicant, Civil Surgeon (Doctor), Interpreter (if needed).
Slide 3: Parts 1 - 4 (Applicant Information)
Part 1: Personal Details (Name, A-Number, DOB). Filled by YOU.
Part 2: Contact Info & Signature. Note: Do not sign until the doctor tells you to.
Part 3: Interpreter details (if translation is needed).
Part 4: Preparer details (if a lawyer filled it out).
Slide 4: Parts 5 - 7 (The Doctor’s Role)
Part 5: Doctor verifies your ID (Passport/Driver's License).
Part 6: Summary of Findings.
Class A: Serious health risks (Inadmissible).
Class B: Minor/Chronic issues (Admissible but noted).
Part 7: Civil Surgeon’s Stamp & Signature.
Slide 5: Part 8 (The Medical Worksheet)
Tuberculosis (TB): Blood test (IGRA) and possible X-ray.
STDs: Tests for Syphilis (Ages 18-44) and Gonorrhea (Ages 18-24).
Mental/Physical Health: Screening for harmful behavior or drug abuse.
Slide 6: Part 10 (Vaccination Record)
Required Vaccines: MMR, Tetanus, Hepatitis B, Varicella, Flu, COVID-19, etc.
Documentation: Doctor records dates or transfers records.
Waivers: If a vaccine is not safe (contraindication), it can be waived.
Slide 7: Important Reminders
Penalty of Perjury: Everyone signs declaring the info is true. Lying has legal consequences.
Validity: Form I-693 is valid for a limited time (usually 2 years from the date of the exam, though this can vary).
Sealed Envelope: The doctor usually gives the form in a sealed envelope; do not open it!
Slide 8: Summary
Complete Part 1 yourself.
See a designated Civil Surgeon.
Complete all required medical tests and vaccines.
Sign at the doctor's office.
Submit to USCIS....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/fzzonqbc-9351/data/document.pdf", "num_examples": 15, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/fzzonqbc- /home/sid/tuning/finetune/backend/output/fzzonqbc-9351/data/fzzonqbc-9351.json...
|
null
|
queued
|
1769685778
|
1769686261
|
NULL
|
/home/sid/tuning/finetune/backend/output/fzzonqbc- /home/sid/tuning/finetune/backend/output/fzzonqbc-9351/adapter...
|
False
|
Edit
Delete
|
|
78c6bb4e-a515-427b-95e7-5c21c8c189a5
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
tubpfwmk-5191
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Breast_Cancer_Informat
|
Breast_Cancer_Information_Sheet.pdf
|
/home/sid/tuning/finetune/backend/output/tubpfwmk- /home/sid/tuning/finetune/backend/output/tubpfwmk-5191/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Complete Paragraph Description
This PDF provide Complete Paragraph Description
This PDF provides basic and essential information about breast cancer, especially for use by healthcare and behavioral health providers in primary care settings. It explains what breast cancer is, how it develops in breast tissue, and the role of ducts, lobules, lymph vessels, and lymph nodes in the spread of the disease. The document describes the difference between benign (non-cancerous) breast lumps and malignant tumors, noting that while most breast lumps are not cancer, some may increase the risk of developing breast cancer. It outlines the main types of breast cancer, including carcinoma in situ, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), invasive ductal carcinoma (IDC), and invasive lobular carcinoma (ILC). The PDF also highlights the importance of early detection through screening such as mammography and explains how cancer can spread through lymph nodes to other parts of the body. Overall, the document aims to improve understanding of breast cancer, its types, and early recognition.
Main Headings
Breast Cancer
What Is Breast Cancer?
Structure of the Breast
Lymph Vessels and Lymph Nodes
Benign Breast Lumps
Main Types of Breast Cancer
Invasive and Non-Invasive Cancers
Early Detection and Screening
Topics Covered
Definition of breast cancer
Breast anatomy (ducts, lobules, lymph nodes)
Difference between benign and malignant lumps
Spread of cancer through lymph nodes
Types of breast cancer
Non-invasive vs invasive cancer
Importance of mammograms
Breast cancer risk factors
Key Points
Breast cancer starts from abnormal cells in the breast.
It mostly affects women, but men can also develop it.
Most breast cancers begin in ducts or lobules.
Lymph nodes play a key role in cancer spread.
Most breast lumps are benign and not cancerous.
DCIS is an early, non-invasive cancer with high cure rates.
IDC is the most common invasive breast cancer.
Early detection greatly improves outcomes.
Important Headings for Notes
1. Breast Structure
Lobules (milk-producing glands)
Ducts (carry milk to nipple)
Fatty and connective tissue
Lymph vessels and lymph nodes
2. Benign Breast Lumps
Fibrocystic changes
Cysts and fibrosis
Usually not life-threatening
3. Non-Invasive Breast Cancer
Carcinoma in situ
Ductal carcinoma in situ (DCIS)
Lobular carcinoma in situ (LCIS)
4. Invasive Breast Cancer
Invasive ductal carcinoma (IDC)
Invasive lobular carcinoma (ILC)
Easy Explanation (Simple Words)
Breast cancer happens when abnormal cells grow uncontrollably in the breast. These cells usually start in the milk ducts or milk-producing glands. Some breast lumps are harmless and not cancer, but certain types can increase the risk of cancer later. Breast cancer can spread through lymph nodes under the arm to other parts of the body. Some cancers stay inside the ducts or lobules and are easier to treat, while others spread into nearby tissue. Finding breast cancer early through tests like mammograms makes treatment much more successful.
Sample Questions (For Exams / Practice)
What is breast cancer?
Which parts of the breast can develop cancer?
What is the difference between benign and malignant breast lumps?
What role do lymph nodes play in breast cancer spread?
Define ductal carcinoma in situ (DCIS).
What is invasive ductal carcinoma (IDC)?
Why is early detection important in breast cancer?
How do mammograms help in breast cancer diagnosis?
Presentation Outline (Simple Slides)
Slide 1 – Title
Breast Cancer: Basic Information
Slide 2 – What Is Breast Cancer?
Definition and overview
Slide 3 – Breast Anatomy
Ducts, lobules, lymph nodes
Slide 4 – Benign vs Malignant Lumps
Key differences
Slide 5 – Types of Breast Cancer
DCIS, LCIS, IDC, ILC
Slide 6 – Cancer Spread
Role of lymph nodes
Slide 7 – Early Detection
Mammograms and screening
Slide 8 – Summary
Key take-home points
If you want next, I can:
turn this into MCQs,
make 1-page exam notes,
create flashcards, or
prepare a ready-to-present PowerPoint script....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/tubpfwmk-5191/data/document.pdf", "num_examples": 22, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/tubpfwmk- /home/sid/tuning/finetune/backend/output/tubpfwmk-5191/data/tubpfwmk-5191.json...
|
null
|
queued
|
1769685836
|
1769686297
|
NULL
|
/home/sid/tuning/finetune/backend/output/tubpfwmk- /home/sid/tuning/finetune/backend/output/tubpfwmk-5191/adapter...
|
False
|
Edit
Delete
|
|
1fb1e3e1-5c2d-4144-9f7d-e00801191038
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
xfwydhiu-7580
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
breast cancer
|
breast cancer
|
/home/sid/tuning/finetune/backend/output/xfwydhiu- /home/sid/tuning/finetune/backend/output/xfwydhiu-7580/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Complete Paragraph Description
The provided do 1. Complete Paragraph Description
The provided documents offer a comprehensive, multi-dimensional view of breast cancer, bridging the gap between genetic science, clinical practice, lifestyle prevention, and patient support. The MedlinePlus Genetics resource establishes the biological foundation, distinguishing between somatic mutations (acquired during life) and germline mutations (inherited, such as BRCA1/BRCA2), and explaining how these defects in tumor suppressor genes lead to uncontrolled cell growth. The clinical article from American Family Physician expands on this by detailing how these genetic factors influence staging and treatment protocols, ranging from chemoprevention for high-risk individuals to pharmacologic management of metastatic disease. The World Cancer Research Fund report adds a critical layer of evidence-based prevention, identifying strong links between lifestyle factors (alcohol, physical activity, and body fatness) and cancer risk, including the nuanced finding that body fatness in young adulthood may be protective while body fatness later in life is a risk. Finally, the Cancer Council Australia guide translates these medical and scientific concepts into practical information for patients, explaining the "triple test" for diagnosis, the emotional impact of the disease, and the available surgical and reconstructive options.
2. Key Points, Headings, and Topics
Topic 1: Genetics and Causes (MedlinePlus Genetics)
Mutation Types:
Somatic Mutations: Acquired during a person's lifetime; not inherited; present only in breast cells.
Germline Mutations: Inherited from a parent; present in all cells; increase the risk of developing cancer.
Key Genes:
BRCA1 & BRCA2: "High penetrance" genes involved in DNA repair. Mutations significantly increase risks of breast, ovarian, and other cancers.
Other Genes: TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome), CDH1, and STK11.
Inheritance: Most hereditary breast cancers follow an autosomal dominant pattern (one copy of the altered gene is sufficient to increase risk).
Topic 2: Lifestyle and Prevention (WCRF Report)
Strong Evidence for Increasing Risk:
Alcohol: Consuming alcoholic drinks increases risk for both pre- and postmenopausal women.
Adult Body Fatness: Greater body fatness in adulthood increases risk (strong evidence for postmenopausal).
Adult Weight Gain: Gaining weight in adulthood increases risk.
Adult Height: Greater linear growth (taller height) is a marker of risk.
Strong Evidence for Decreasing Risk:
Physical Activity: Being physically active (including vigorous activity) reduces risk.
Breastfeeding: Protects against breast cancer.
The "Young Adulthood Paradox": Greater body fatness between ages 18–30 actually decreases the risk of both pre- and postmenopausal breast cancer, unlike body fatness in later life.
Topic 3: Clinical Diagnosis and Staging (Cancer Council & AAPF)
The Triple Test: Physical examination, Imaging (Mammogram/Ultrasound), and Biopsy.
Tumor Subtypes:
Hormone Receptor Positive (ER+/PR+): Fueled by estrogen/progesterone.
HER2 Positive: Driven by an overexpression of the HER2 protein.
Triple Negative: Lacks all three receptors; aggressive; treated with chemotherapy/immunotherapy.
Staging:
Stage 0 (DCIS): Non-invasive; confined to ducts.
Stage I-III: Non-metastatic (Early to Locally Advanced).
Stage IV: Metastatic (Spread to distant organs like bone/liver).
Topic 4: Treatment and Management (AAPF & Cancer Council)
Surgery:
Breast-Conserving (Lumpectomy): Removal of tumor + margins; usually requires radiation.
Mastectomy: Removal of the whole breast; option for reconstruction.
Systemic Therapy:
Neoadjuvant: Given before surgery to shrink tumors (common in HER2+ or Triple Negative).
Adjuvant: Given after surgery to kill remaining cells.
Pharmacology:
Endocrine Therapy: Tamoxifen (premenopausal) or Aromatase Inhibitors (postmenopausal).
Targeted Therapy: Trastuzumab (Herceptin) for HER2+ cancers.
Bone Health: Bisphosphonates (e.g., Zoledronic acid) to prevent bone loss during treatment.
3. Review Questions
Genetics: What is the difference between somatic mutations and germline mutations in breast cancer?
Lifestyle: According to the WCRF report, how does body fatness in young adulthood (ages 18-30) affect breast cancer risk compared to body fatness in later adulthood?
Pathology: What are the three main receptor markers used to classify breast cancer subtypes?
Treatment: Why is chemotherapy often the core treatment for Triple Negative breast cancer?
Prevention: Name two lifestyle factors identified as having "strong evidence" for increasing the risk of breast cancer.
Staging: What is the defining characteristic of Stage 0 (DCIS) breast cancer compared to Stage I?
4. Easy Explanation (Simplified Summary)
What causes it?
Breast cancer happens when cells in the breast grow out of control. This can be due to:
Random mistakes (Somatic): Cell damage that happens as you age.
Family history (Germline): Inherited genes (like BRCA1/2) that don't fix damaged DNA properly.
How do we find it?
Doctors use a "triple test": feeling for lumps, taking pictures (mammograms/ultrasounds), and taking a tiny sample (biopsy) to check the cancer's "ID card" (receptors).
How do lifestyle choices matter?
Bad habits: Drinking alcohol and gaining weight as an adult increase your risk.
Good habits: Exercise and breastfeeding lower your risk.
Surprising fact: Being heavier in your late teens/early 20s might actually lower your risk, but being heavier later in life raises it.
How is it treated?
Surgery: Doctors either remove the lump (lumpectomy) or the whole breast (mastectomy).
Medicine:
If the cancer eats hormones -> Block the hormones.
If the cancer has HER2 protein -> Use targeted drugs.
If the cancer has none of these (Triple Negative) -> Use chemotherapy.
5. Presentation Outline
Slide 1: Title
Breast Cancer: From Genetics to Treatment
Integrating Genetics, Lifestyle, and Clinical Care
Slide 2: The Genetic Blueprint (MedlinePlus)
Two types of mutations:
Somatic: Acquired during life; not inherited.
Germline: Inherited (e.g., BRCA1, BRCA2); autosomal dominant pattern.
Mechanism: Mutations in tumor suppressor genes (like BRCA) prevent DNA repair, leading to uncontrolled cell growth.
Slide 3: Lifestyle and Prevention (WCRF Report)
Increases Risk:
Alcohol consumption.
Greater body fatness in adulthood.
Adult weight gain.
Decreases Risk:
Physical activity (Vigorous & Total).
Breastfeeding.
The Paradox:
Young Adulthood (18-30): Higher body fatness = Lower risk.
Later Adulthood: Higher body fatness = Higher risk.
Slide 4: Diagnosis & Staging (Clinical Guide)
The Triple Test: Exam + Imaging + Biopsy.
Tumor Subtypes:
ER/PR Positive (Hormone fueled).
HER2 Positive (Protein driven).
Triple Negative (Chemo/Immunotherapy dependent).
Stages:
0 (DCIS): Non-invasive.
I-III: Localized/Locally Advanced.
IV: Metastatic (Spread to bones, liver, lung).
Slide 5: Treatment Pathways
Surgery: Lumpectomy (+Radiation) vs. Mastectomy (+/- Reconstruction).
Systemic Therapy:
Neoadjuvant: Before surgery (to shrink).
Adjuvant: After surgery (to prevent return).
Supportive Care:
Bisphosphonates for bone health (prevents osteoporosis/fractures).
Pain management and lymphedema care.
Slide 6: Summary & Takeaways
Genetics Matter: Family history (BRCA) significantly impacts risk and screening.
Lifestyle Matters: Limit alcohol, stay active, maintain healthy weight (especially after menopause).
Personalized Medicine: Treatment is entirely dependent on the specific tumor subtype (ER/PR/HER2).
Holistic Care: Combining surgery, drugs, lifestyle, and emotional support yields the best outcomes....
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/xfwydhiu-7580/data/document.pdf", "num_examples": 42, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/xfwydhiu- /home/sid/tuning/finetune/backend/output/xfwydhiu-7580/data/xfwydhiu-7580.json...
|
null
|
queued
|
1769686113
|
1769687384
|
NULL
|
/home/sid/tuning/finetune/backend/output/xfwydhiu- /home/sid/tuning/finetune/backend/output/xfwydhiu-7580/adapter...
|
False
|
Edit
Delete
|
|
7648ce46-b219-4c38-b02b-279ba3936f0f
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
ruugmxoe-6879
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Breast cancer
|
breast cancer
|
/home/sid/tuning/finetune/backend/output/ruugmxoe- /home/sid/tuning/finetune/backend/output/ruugmxoe-6879/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. Introduction
Key Points
Breast cancer is 1. Introduction
Key Points
Breast cancer is the most common cancer in women
Second leading cause of cancer-related death in women
Can be detected early through screening
Treated using surgery, chemotherapy, radiation, hormonal and targeted therapy
Easy Explanation
Breast cancer is a disease where abnormal cells grow uncontrollably in breast tissue. It usually develops silently and is often found during routine screening like mammography. Early diagnosis greatly improves survival and treatment success.
2. Breast Anatomy (Basic Understanding)
Key Points
Breasts contain lobules (milk-producing glands)
Lobules connect to ducts that open at the nipple
Supported by Cooper’s ligaments
Located over the pectoralis major muscle
Easy Explanation
The breast is made of glands, ducts, fat, and connective tissue. Cancer usually starts in the ducts or lobules, where cells divide frequently.
3. Types of Breast Cancer
Key Points
Ductal carcinoma – most common
Lobular carcinoma – harder to detect
Invasive vs non-invasive (in situ)
Can spread locally or to distant organs
Easy Explanation
Most breast cancers begin in milk ducts. Some remain confined, while others invade nearby tissue and spread to lymph nodes or organs.
4. Risk Factors for Breast Cancer
Key Points
Increasing age
Female gender
Family history (BRCA1, BRCA2)
Early menarche, late menopause
Late first pregnancy or no pregnancy
Hormone replacement therapy
Obesity, alcohol, radiation exposure
Easy Explanation
Anything that increases lifetime exposure to estrogen or damages DNA can raise breast cancer risk. Genetics plays a strong role, especially in younger women.
5. Epidemiology
Key Points
1 in 8 women may develop breast cancer
Most cases occur after age 40
Mortality decreasing in developed countries
Higher death rates in low-resource regions
Easy Explanation
Breast cancer is common worldwide. Early screening and advanced treatment have reduced deaths in some countries, but outcomes still vary greatly.
6. Pathophysiology & Molecular Subtypes
Key Points
Luminal A – ER/PR positive, best prognosis
Luminal B – ER positive, HER2 positive
HER2-enriched – aggressive but treatable
Triple-negative – aggressive, poor prognosis
Easy Explanation
Breast cancer behavior depends on hormone receptors and HER2 status. These markers guide treatment and predict outcomes.
7. Histological Types
Key Points
Invasive ductal carcinoma (most common)
Invasive lobular carcinoma
Mucinous carcinoma
Tubular carcinoma
Medullary carcinoma
Easy Explanation
Under the microscope, breast cancers look different. Some grow slowly and others aggressively. These differences help doctors plan treatment.
8. Clinical Presentation
Key Points
Often asymptomatic early
Painless breast lump
Nipple discharge or inversion
Skin changes (peau d’orange)
Axillary lymph node swelling
Easy Explanation
Most early breast cancers cause no pain. Any new lump or skin change should be evaluated promptly.
9. Diagnostic Evaluation
Key Points
Mammography (screening & diagnosis)
Ultrasound (dense breasts)
MRI (high-risk or complex cases)
Core needle biopsy (gold standard)
BI-RADS classification (0–6)
Easy Explanation
Imaging finds suspicious lesions, but only a biopsy confirms cancer. BI-RADS helps decide follow-up and treatment urgency.
10. Staging of Breast Cancer (TNM System)
Key Points
T – Tumor size
N – Lymph node involvement
M – Distant metastasis
Stages range from 0 to IV
Easy Explanation
Staging tells how advanced the cancer is. Early stages are localized, while stage IV indicates spread to distant organs.
11. Treatment of Breast Cancer
A. Early Breast Cancer
Surgery (lumpectomy or mastectomy)
Sentinel lymph node biopsy
Radiation therapy
Chemotherapy (based on risk)
Hormonal therapy if ER/PR positive
B. Locally Advanced Breast Cancer
Neoadjuvant chemotherapy
Surgery + radiation
Hormonal therapy if indicated
C. Metastatic Breast Cancer
Systemic therapy
Palliative radiation
Surgery only for symptom control
Easy Explanation
Treatment depends on stage and tumor type. Early cancer aims for cure, advanced disease focuses on control and quality of life.
12. Surgical Options
Key Points
Lumpectomy (breast conserving)
Simple mastectomy
Modified radical mastectomy
Sentinel node biopsy
Axillary lymph node dissection
Easy Explanation
Surgery removes the tumor and helps determine spread. Less aggressive surgery is now possible due to better systemic treatments.
13. Radiation Therapy
Key Points
Whole breast radiation
Partial breast irradiation
Post-mastectomy radiation
Reduces local recurrence
Easy Explanation
Radiation destroys microscopic cancer cells left after surgery, lowering the chance of cancer coming back.
14. Medical Oncology
Key Points
Chemotherapy (anthracyclines, taxanes)
Hormonal therapy (tamoxifen, aromatase inhibitors)
Targeted therapy (trastuzumab)
Immunotherapy (checkpoint inhibitors)
Easy Explanation
Medicines target fast-growing cancer cells, hormone pathways, or specific receptors to stop tumor growth.
15. Complications of Treatment
Key Points
Surgical: pain, infection, scarring
Chemotherapy: hair loss, nausea, neuropathy
Radiation: skin changes, fatigue
Hormonal therapy: hot flashes, fatigue
Lymphedema
Easy Explanation
While treatments are effective, they may cause side effects that require long-term care and monitoring.
16. Prognosis
Key Points
Stage 0–I: nearly 100% survival
Stage II: ~93% survival
Stage III: ~72% survival
Stage IV: ~22% survival
Easy Explanation
Earlier detection means better survival. Advanced disease has a poorer prognosis but can still be managed.
17. Prevention & Patient Education
Key Points
Regular screening
Lifestyle modification
Genetic counseling for high-risk patients
Treatment adherence
Long-term follow-up
Easy Explanation
Awareness, screening, and early treatment save lives. Education empowers patients to seek timely care.
18. Healthcare Team Approach
Key Points
Multidisciplinary care
Surgeons, oncologists, radiologists, nurses
Coordinated diagnosis, treatment, follow-up
Easy Explanation
Breast cancer care requires teamwork to ensure accurate diagnosis, effective treatment, and emotional support.
If you want next:
📊 PowerPoint-ready slides
❓ MCQs / short questions / viva questions
🧠 Ultra-simple exam revision notes
📝 One-page summary sheet
Just tell me — I’ve got you 🌸...
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/ruugmxoe-6879/data/document.pdf", "num_examples": 253, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/ruugmxoe- /home/sid/tuning/finetune/backend/output/ruugmxoe-6879/data/ruugmxoe-6879.json...
|
null
|
queued
|
1769862195
|
1769863010
|
NULL
|
/home/sid/tuning/finetune/backend/output/ruugmxoe- /home/sid/tuning/finetune/backend/output/ruugmxoe-6879/adapter...
|
False
|
Edit
Delete
|
|
8ad394f2-83a2-4824-9a77-1796df614f35
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
ekbckppy-6402
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
breast cancer
|
breast cancer
|
/home/sid/tuning/finetune/backend/output/ekbckppy- /home/sid/tuning/finetune/backend/output/ekbckppy-6402/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Key Points
Breast cancer is a group of diseases Key Points
Breast cancer is a group of diseases with different molecular subtypes
Most tumors arise from ductal or lobular epithelium
Most common life-threatening cancer in women worldwide
Often asymptomatic in early stages
Commonly detected by screening mammography
Triple assessment: clinical exam + imaging + biopsy
Easy Explanation
Breast cancer is not a single disease but many types of tumors that start in breast ducts or lobules. Many women have no symptoms at first, which is why screening is very important. Early diagnosis improves survival and allows curative treatment.
Breast Cancer 3
2. Anatomy of the Breast
Key Points
Located on the anterior chest wall
Lies over pectoralis major muscle
Each breast has 15–20 lobes
Lobes contain lobules that produce milk
Supported by ligaments
Fat gives breast its shape and size
Easy Explanation
The breast is made of glands that produce milk, ducts that carry milk, fat for shape, and ligaments for support. Cancer usually starts where cells divide frequently—inside ducts or lobules.
Breast Cancer 3
3. Pathophysiology
Key Points
Cancer develops due to genetic and molecular alterations
Leads to uncontrolled cell growth
Tumors classified by receptor status:
Estrogen receptor (ER)
Progesterone receptor (PR)
HER2 receptor
Breast cancer behaves as distinct diseases, not one entity
Easy Explanation
Normal breast cells become cancerous after DNA damage causes them to grow uncontrollably. The presence or absence of hormone and HER2 receptors determines tumor behavior and treatment.
Breast Cancer 3
4. Molecular Subtypes
Key Points
Luminal A – ER positive, best prognosis
Luminal B – ER positive, more aggressive
HER2-positive – aggressive but treatable
Basal-like / Triple-negative – aggressive, poor prognosis
Easy Explanation
Breast cancers are divided into subtypes based on receptors. These subtypes explain why some cancers grow slowly while others spread rapidly and require stronger treatment.
Breast Cancer 3
5. Histological Types
Key Points
Invasive ductal carcinoma (75–85%)
Invasive lobular carcinoma (<15%)
Medullary carcinoma (~5%)
Mucinous carcinoma (<5%)
Tubular carcinoma (1–2%)
Papillary carcinoma (1–2%)
Metaplastic carcinoma (<1%)
Easy Explanation
Under the microscope, breast cancers look different. Some types grow slowly and have good outcomes, while others are aggressive and spread early.
Breast Cancer 3
6. Etiology / Risk Factors
Key Points
Female gender
Increasing age
Family history of breast or ovarian cancer
BRCA1 / BRCA2 mutations
Early menarche, late menopause
Late first pregnancy or no pregnancy
Hormone replacement therapy
Obesity and alcohol
Radiation exposure
Easy Explanation
Breast cancer risk increases with prolonged hormone exposure, genetic mutations, and certain lifestyle factors. Some risks are modifiable, others are not.
Breast Cancer 3
7. Family History & Genetics
Key Points
Risk increases 4–5 times with first-degree relatives
Male breast cancer suggests genetic mutation
BRCA mutations strongly linked
Genetic risk assessment tools available
Easy Explanation
Women with close relatives affected by breast or ovarian cancer are at higher risk. Genetic testing helps identify those who need close monitoring or preventive strategies.
Breast Cancer 3
8. Reproductive & Hormonal Factors
Key Points
Early menarche
Late menopause
Nulliparity
Late age at first pregnancy
Oral contraceptives (temporary risk increase)
Hormone replacement therapy (especially combined)
Easy Explanation
Longer exposure to estrogen increases the chance of breast cancer. Hormonal medications can influence risk depending on duration and type used.
Breast Cancer 3
9. Lifestyle & Environmental Factors
Key Points
Obesity (especially postmenopausal)
Sedentary lifestyle
Alcohol consumption
Western diet
Radiation exposure (especially during adolescence)
Easy Explanation
Lifestyle plays a major role in breast cancer risk. Healthy diet, exercise, and avoiding unnecessary radiation can reduce risk.
Breast Cancer 3
10. Epidemiology
Key Points
Most common cancer in women globally
Incidence higher in developed countries
Mortality decreasing due to screening and treatment
Median age at diagnosis: 63 years
Easy Explanation
Breast cancer is common worldwide. Better screening and modern treatment have reduced deaths, especially in countries with good healthcare systems.
Breast Cancer 3
11. Clinical Features
Key Points
Often asymptomatic early
Painless breast lump
Skin dimpling or thickening
Nipple inversion or discharge
Enlarged axillary lymph nodes
Easy Explanation
Early breast cancer may cause no symptoms. Any new breast change should be investigated immediately.
Breast Cancer 3
12. Diagnosis
Key Points
Clinical examination
Mammography
Ultrasound
MRI (high-risk cases)
Needle biopsy (confirmation)
Easy Explanation
Imaging detects suspicious lesions, but biopsy is required to confirm cancer and determine its type.
Breast Cancer 3
13. Prognostic Factors
Key Points
Tumor size
Lymph node involvement
Histologic grade
ER / PR status
HER2 status
Response to therapy
Easy Explanation
Certain tumor features help predict survival and guide treatment decisions. Node-negative and hormone-positive cancers have better outcomes.
Breast Cancer 3
14. Prognosis
Key Points
Survival improving over decades
Early-stage cancers have high survival
HER2 prognosis improved with targeted therapy
Triple-negative cancers have poorer outcomes
Easy Explanation
Outcome depends on cancer stage and subtype. Advances in targeted therapy have significantly improved survival.
Breast Cancer 3
15. Associated Conditions
Key Points
Increased cardiovascular disease risk
Treatment-related cardiotoxicity
Long-term follow-up required
Easy Explanation
Breast cancer survivors may develop heart problems due to treatment, making long-term monitoring essential.
Breast Cancer 3
✅ This format is suitable for
Making points
Creating questions / MCQs
Lecture slides
Exam answers
Easy revision notes
If you want next:
📘 MCQs from this PDF
🧾 One-page exam summary
📊 PowerPoint slides
🧠 Very short viva answers
Just tell me what you want next 🌸...
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/ekbckppy-6402/data/document.pdf", "num_examples": 176, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/ekbckppy- /home/sid/tuning/finetune/backend/output/ekbckppy-6402/data/ekbckppy-6402.json...
|
null
|
queued
|
1769862356
|
1769863019
|
NULL
|
/home/sid/tuning/finetune/backend/output/ekbckppy- /home/sid/tuning/finetune/backend/output/ekbckppy-6402/adapter...
|
False
|
Edit
Delete
|
|
cd8ef463-6b0c-48ae-9ba9-285377c04c5a
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
wovyxoam-9487
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
cardialogy
|
cardialogy
|
/home/sid/tuning/finetune/backend/output/wovyxoam- /home/sid/tuning/finetune/backend/output/wovyxoam-9487/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
As soon as the PDF content is accessible, I will d As soon as the PDF content is accessible, I will deliver exactly this structure, just like before:
✔ FULL, PROPER FORMAT (Guaranteed)
Main Topic Title
Introduction
Key Points
Easy Explanation
Each Topic / Section
Topic Heading
Key Points (bullets)
Easy Explanation (simple language)
Subtopics clearly separated
No application names mentioned
Ready for:
📌 Points
❓ Questions / MCQs
🧠 Viva
📊 Presentations
📝 Exam answers
Same clarity. Same exam-friendly style. Same clean structure.
🔹 What I need from you (one small step)
Please do ONE of the following:
Confirm: “Yes, proceed with pdf 2.....pdf”
Or paste the first page / topic title from the PDF
Or say: “Use the same format as before” (I already know what that format is)
The moment you confirm, I’ll generate the FULL, PROPER FORMAT immediately 🌸
You’re doing this the right way — just one final step and we’re good 👍...
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/wovyxoam-9487/data/document.pdf", "num_examples": 820, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/wovyxoam- /home/sid/tuning/finetune/backend/output/wovyxoam-9487/data/wovyxoam-9487.json...
|
null
|
queued
|
1769862558
|
1769864166
|
NULL
|
/home/sid/tuning/finetune/backend/output/wovyxoam- /home/sid/tuning/finetune/backend/output/wovyxoam-9487/adapter...
|
False
|
Edit
Delete
|
|
0307c257-390d-42ac-b06c-33d26b3f1bf4
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
ufsdweho-6152
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
A Christmas carol
|
This is the new version of Christmas
|
/home/sid/tuning/finetune/backend/output/ufsdweho- /home/sid/tuning/finetune/backend/output/ufsdweho-6152/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
MARLEY'S GHOST
THE FIRST OF THE
THREE SPIRI MARLEY'S GHOST
THE FIRST OF THE
THREE SPIRITS
THE SECOND OF THE
THREE SPIRITS
THE LAST OF THE SPIRITS
THE END OF IT
LIST OF ILLUSTRATIONS
IN COLOUR
IN BLACK AND WHITE
...
|
{"num_examples": 532, "bad_lines": {"num_examples": 532, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/ufsdweho- /home/sid/tuning/finetune/backend/output/ufsdweho-6152/data/ufsdweho-6152.json...
|
{"message": "Training failed: You can& {"message": "Training failed: You can't train a model that has been loaded in 8-bit or 4-bit precision on a different device than the one you're training on. Make sure you loaded the model on the correct device using for example `device_map={'':torch.cuda.current_device()}` or `device_map={'':torch.xpu.current_device()}`"}...
|
failed
|
1764310111
|
1764312699
|
NULL
|
/home/sid/tuning/finetune/backend/output/ufsdweho- /home/sid/tuning/finetune/backend/output/ufsdweho-6152/adapter...
|
False
|
Edit
Delete
|
|
49b52995-feda-4b3f-a9c3-4aa8be870e01
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
bzudmnnm-1917
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
THE NIGHT OF CHRISTMAS E
|
This is the new version of Christmas data.
|
/home/sid/tuning/finetune/backend/output/bzudmnnm- /home/sid/tuning/finetune/backend/output/bzudmnnm-1917/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
“The Night of Christmas Eve” is a magical-folklori “The Night of Christmas Eve” is a magical-folkloric tale set in a Ukrainian village on Christmas Eve. Blending humor, romance, and supernatural elements, Gogol transports the reader into a world where devils, witches, and enchanted happenings coexist with village traditions.
The story follows:
Vakula the Blacksmith
A hardworking but impulsive blacksmith who is hopelessly in love with Oksana, a beautiful yet vain girl. Oksana mocks him, saying she will only marry him if he brings her the Tsaritsa’s slippers—an impossible task.
The Devil’s Mischief
A devil, angry at Vakula for painting religious icons that depict demons in humiliating ways, decides to cause trouble. On Christmas Eve he steals the moon, summons a snowstorm, and teams up with the witch Solokha (who happens to be Vakula’s mother) in a comic series of encounters involving hidden lovers in sacks.
Vakula’s Fantastic Journey
After overhearing Oksana’s demand, Vakula strikes a deal with the devil and flies on his back to St. Petersburg. Through a twist of luck and boldness, he actually obtains the Tsaritsa’s slippers.
A Warm Ending
Vakula returns triumphantly, Oksana realizes she truly loves him, and the tale ends with a joyful holiday celebration—full of music, warmth, and the spirit of Ukrainian Christmas tradition.
Tone & Style
Gogol mixes:
Folklore
Comedy
Romantic adventure
Supernatural fantasy
The story is vivid, whimsical, and rooted deeply in Ukrainian rural culture and Christmas customs.
...
|
{"num_examples": 255, "bad_lines": {"num_examples": 255, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/bzudmnnm- /home/sid/tuning/finetune/backend/output/bzudmnnm-1917/data/bzudmnnm-1917.json...
|
{"message": "Training failed: You can& {"message": "Training failed: You can't train a model that has been loaded in 8-bit or 4-bit precision on a different device than the one you're training on. Make sure you loaded the model on the correct device using for example `device_map={'':torch.cuda.current_device()}` or `device_map={'':torch.xpu.current_device()}`"}...
|
failed
|
1764310987
|
1764312774
|
NULL
|
/home/sid/tuning/finetune/backend/output/bzudmnnm- /home/sid/tuning/finetune/backend/output/bzudmnnm-1917/adapter...
|
False
|
Edit
Delete
|
|
abceabb5-3354-4f77-bc56-26590b38bf63
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
uubecvgl-9574
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
The Legend of Babushka
|
This is the new version of Christmas data
|
/home/sid/tuning/finetune/backend/output/uubecvgl- /home/sid/tuning/finetune/backend/output/uubecvgl-9574/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
“The Legend of Babushka” tells the story of an old “The Legend of Babushka” tells the story of an old Russian woman who is visited by the Three Wise Men on their journey to see the newborn Jesus. They invite her to come, but she is too busy with her housework. When she changes her mind and tries to follow them, she cannot find the child. Ever since, she wanders each Christmas, giving small gifts to children as she continues her search for the Christ Child....
|
{"num_examples": 8, "bad_lines": 0 {"num_examples": 8, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/uubecvgl- /home/sid/tuning/finetune/backend/output/uubecvgl-9574/data/uubecvgl-9574.json...
|
{"message": "Training failed: You can& {"message": "Training failed: You can't train a model that has been loaded in 8-bit or 4-bit precision on a different device than the one you're training on. Make sure you loaded the model on the correct device using for example `device_map={'':torch.cuda.current_device()}` or `device_map={'':torch.xpu.current_device()}`"}...
|
failed
|
1764312265
|
1764312325
|
NULL
|
/home/sid/tuning/finetune/backend/output/uubecvgl- /home/sid/tuning/finetune/backend/output/uubecvgl-9574/adapter...
|
False
|
Edit
Delete
|
|
e4dffdab-9f24-4368-977c-25eb1a2a48cf
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
iouivtmm-2239
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
The Snowman
|
This is the new version of Christmas data
|
/home/sid/tuning/finetune/backend/output/iouivtmm- /home/sid/tuning/finetune/backend/output/iouivtmm-2239/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
“The Snowman” is about a snowman who falls in love “The Snowman” is about a snowman who falls in love with a warm stove he sees inside a house. He doesn’t understand that heat will melt him, and when spring comes, he melts away....
|
{"num_examples": 12, "bad_lines": {"num_examples": 12, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/iouivtmm- /home/sid/tuning/finetune/backend/output/iouivtmm-2239/data/iouivtmm-2239.json...
|
{"message": "Training failed: You can& {"message": "Training failed: You can't train a model that has been loaded in 8-bit or 4-bit precision on a different device than the one you're training on. Make sure you loaded the model on the correct device using for example `device_map={'':torch.cuda.current_device()}` or `device_map={'':torch.xpu.current_device()}`"}...
|
failed
|
1764312844
|
1764312993
|
NULL
|
/home/sid/tuning/finetune/backend/output/iouivtmm- /home/sid/tuning/finetune/backend/output/iouivtmm-2239/adapter...
|
False
|
Edit
Delete
|
|
03ecaf9b-531b-4f74-b57b-b98cd6a4c706
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
jwxgstaz-4757
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
A Christmas Dream,
|
This is the new version of Christmas data
|
/home/sid/tuning/finetune/backend/output/jwxgstaz- /home/sid/tuning/finetune/backend/output/jwxgstaz-4757/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
“A Christmas Dream, and How It Came to Be True”:
“A Christmas Dream, and How It Came to Be True”:
The story is about a girl named Effie who is disappointed with her Christmas gifts because she already has many toys. That night, she dreams of visiting a poor family who has nothing for Christmas. In the dream, she gives them her own toys and clothes, and she sees how happy it makes them. When she wakes up, she understands the true meaning of Christmas—kindness and giving. She decides to make her dream come true by sharing her gifts with a real needy family....
|
{"num_examples": 471, "bad_lines": {"num_examples": 471, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/jwxgstaz- /home/sid/tuning/finetune/backend/output/jwxgstaz-4757/data/jwxgstaz-4757.json...
|
{"message": "Training failed: You can& {"message": "Training failed: You can't train a model that has been loaded in 8-bit or 4-bit precision on a different device than the one you're training on. Make sure you loaded the model on the correct device using for example `device_map={'':torch.cuda.current_device()}` or `device_map={'':torch.xpu.current_device()}`"}...
|
failed
|
1764313498
|
1764316230
|
NULL
|
/home/sid/tuning/finetune/backend/output/jwxgstaz- /home/sid/tuning/finetune/backend/output/jwxgstaz-4757/adapter...
|
False
|
Edit
Delete
|
|
d426de6d-15e7-45dd-8c2f-568e70ed9fdb
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
nvuoizwm-7837
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
The Elves Jacob and Wilh
|
This is the new version of Christmas data
|
/home/sid/tuning/finetune/backend/output/nvuoizwm- /home/sid/tuning/finetune/backend/output/nvuoizwm-7837/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
1. The Elves and the Shoemaker
A poor shoemaker r 1. The Elves and the Shoemaker
A poor shoemaker receives secret help from tiny elves who come at night to finish his work. After the shoemaker and his wife sew clothes for them in gratitude, the elves happily dance away and never return.
2. The Elves and the Girl (or The Elves and the Serving-Maid)
A curious serving girl watches elves sneak into the house through cracks and crevices. She startles them by marking their entry point with a line of peas, causing them to slip. Angry, the elves leave the house forever.
3. The Elves and the Man Who Traveled to See Them
A man visits the elves' underground dwelling. They treat him kindly and give him gifts, but when greed leads him to return uninvited, he loses what he gained and learns not to abuse their generosity....
|
{"num_examples": 35, "bad_lines": {"num_examples": 35, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/nvuoizwm- /home/sid/tuning/finetune/backend/output/nvuoizwm-7837/data/nvuoizwm-7837.json...
|
{"message": "Training failed: `Acceler {"message": "Training failed: `AcceleratorState` object has no attribute `distributed_type`. This happens if `AcceleratorState._reset_state()` was called and an `Accelerator` or `PartialState` was not reinitialized."}...
|
failed
|
1764312009
|
1764312324
|
NULL
|
/home/sid/tuning/finetune/backend/output/nvuoizwm- /home/sid/tuning/finetune/backend/output/nvuoizwm-7837/adapter...
|
False
|
Edit
Delete
|
|
6bae65a2-1788-4e37-a147-a84aa3a0173a
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
xevyo-base-v1
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo
|
AI assistant with a single unchangeable identity, AI assistant with a single unchangeable identity, representing the vision, values, and purpose of Dr. Anmol Kapoor....
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
NULL
|
NULL
|
NULL
|
Trained incrementally on curated instruction–respo Trained incrementally on curated instruction–response pairs with embedded chain-of-thought data, it maintains logical coherence, contextual awareness, and factual accuracy....
|
{"num_examples": 1, "bad_lines": 0 {"num_examples": 1, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/data/xevyo-base-v1.json...
|
{"train_runtime": 599.3462, "train_sam {"train_runtime": 599.3462, "train_samples_per_second": 2.67, "train_steps_per_second": 0.334, "total_flos": 8579520714768384.0, "train_loss": 0.2602055296301842, "epoch": 14.296296296296296, "step": 200}...
|
completed
|
1762626468
|
1762626468
|
NULL
|
NULL
|
True
|
Edit
Delete
|
|
b0a28646-1043-4648-a0f9-13b684bfac38
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
hunsxdfl-4743
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Economic
|
Economic development
|
/home/sid/tuning/finetune/backend/output/hunsxdfl- /home/sid/tuning/finetune/backend/output/hunsxdfl-4743/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Economic growth health and poverty
|
{"num_examples": 163, "bad_lines": {"num_examples": 163, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/hunsxdfl- /home/sid/tuning/finetune/backend/output/hunsxdfl-4743/data/hunsxdfl-4743.json...
|
{"train_runtime": 651.4982, "train_sam {"train_runtime": 651.4982, "train_samples_per_second": 2.456, "train_steps_per_second": 0.307, "total_flos": 7555123985276928.0, "train_loss": 0.516647665053606, "epoch": 9.536585365853659, "step": 200}...
|
completed
|
1764307874
|
1764308985
|
NULL
|
/home/sid/tuning/finetune/backend/output/hunsxdfl- /home/sid/tuning/finetune/backend/output/hunsxdfl-4743/adapter...
|
False
|
Edit
Delete
|
|
448a4ad8-de1e-41f1-81cc-17ad98c5b180
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
vfqewudj-1695
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-new
|
New model with Economy Book knowledge
|
/home/sid/tuning/finetune/backend/output/vfqewudj- /home/sid/tuning/finetune/backend/output/vfqewudj-1695/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
A common Sense Guide to the Economy Book By: Thoma A common Sense Guide to the Economy Book By: Thomas Sowell
This is a book about economics guide and bellow are the chapters name:
WHAT IS ECONOMICS?
THE ROLE OF PRICES
PRICES AND MARKETS
Price Controls
An Overview of Prices
INDUSTRY AND COMMERCE
The Rise and Fall of Businesses
The Role of Profits–and Losses
The Economics of Big Business
Regulation and Anti-Trust Laws
Market and Non-Market Economies
WORK AND PAY
Productivity and Pay
Minimum Wage Laws
Special Problems in Labor Markets
TIME AND RISK
Investment
Stocks, Bonds and Insurance
Special Problems of Time and Risk
THE NATIONAL ECONOMY
National Output
Money and the Banking System
Government Functions
Government Finance
Special Problems in the National Economy
THE INTERNATIONAL ECONOMY
International Trade
International Transfers of Wealth
International Disparities in Wealth
SPECIAL ECONOMIC ISSUES
Myths About Markets
“Non-Economic” Values
The History of Economics
Parting Thoughts...
|
{"num_examples": 4737, "bad_lines" {"num_examples": 4737, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/vfqewudj- /home/sid/tuning/finetune/backend/output/vfqewudj-1695/data/vfqewudj-1695.json...
|
{"train_runtime": 654.8482, "train_sam {"train_runtime": 654.8482, "train_samples_per_second": 2.443, "train_steps_per_second": 0.305, "total_flos": 7878114829615104.0, "train_loss": 1.3694590425491333, "epoch": 0.33769523005487545, "step": 200}...
|
completed
|
1762626468
|
1764308975
|
NULL
|
/home/sid/tuning/finetune/backend/output/vfqewudj- /home/sid/tuning/finetune/backend/output/vfqewudj-1695/adapter...
|
False
|
Edit
Delete
|
|
bcdb97fe-5967-4e33-b01b-ef1f0fbfb560
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
mfcdvyme-9289
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
mTmodel_1765016141
|
Filtered merged training 6-12
|
/home/sid/tuning/finetune/backend/output/mfcdvyme- /home/sid/tuning/finetune/backend/output/mfcdvyme-9289/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
Contain lots of data various category like econimi Contain lots of data various category like econimics, medical, historical...
|
{"input_type": "file", "source {"input_type": "file", "source": "/home/sid/tuning/finetune/backend/output/mfcdvyme-9289/data/document.json", "num_examples": 47886, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/mfcdvyme- /home/sid/tuning/finetune/backend/output/mfcdvyme-9289/data/mfcdvyme-9289.json...
|
{"train_runtime": 654.8482, "train_sam {"train_runtime": 654.8482, "train_samples_per_second": 2.443, "train_steps_per_second": 0.305, "total_flos": 7878114829615104.0, "train_loss": 1.3694590425491333, "epoch": 0.33769523005487545, "step": 200}...
|
completed
|
1765016142
|
1765041447
|
NULL
|
/home/sid/tuning/finetune/backend/output/mfcdvyme- /home/sid/tuning/finetune/backend/output/mfcdvyme-9289/adapter...
|
False
|
Edit
Delete
|
|
c46e3cce-59ea-46c4-8d9d-fe2e7c859dd3
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
tlcrvwcu-4698
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
Christmas
|
This is the new version of Christmas data
|
/home/sid/tuning/finetune/backend/output/tlcrvwcu- /home/sid/tuning/finetune/backend/output/tlcrvwcu-4698/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
The History of Christmas traditions, Christmas car The History of Christmas traditions, Christmas cards, Mince pies ,Carol singing, The times of no Christmas. ...
|
{"num_examples": 88, "bad_lines": {"num_examples": 88, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/tlcrvwcu- /home/sid/tuning/finetune/backend/output/tlcrvwcu-4698/data/tlcrvwcu-4698.json...
|
{"train_runtime": 670.6482, "train_sam {"train_runtime": 670.6482, "train_samples_per_second": 2.386, "train_steps_per_second": 0.298, "total_flos": 7306847131287552.0, "train_loss": 0.34121644526720046, "epoch": 18.181818181818183, "step": 200}...
|
completed
|
1764309633
|
1764310716
|
NULL
|
/home/sid/tuning/finetune/backend/output/tlcrvwcu- /home/sid/tuning/finetune/backend/output/tlcrvwcu-4698/adapter...
|
False
|
Edit
Delete
|
|
bf45c8a4-9b61-4075-a986-f328b8932cec
|
8684964a-bab1-4235-93a8-5fd5e24a1d0a
|
thsndkzt-8310
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
The Gift of the Magi
|
This is the new version of Christmas data
|
/home/sid/tuning/finetune/backend/output/thsndkzt- /home/sid/tuning/finetune/backend/output/thsndkzt-8310/merged_fp16_hf...
|
xevyo
|
/home/sid/tuning/finetune/backend/output/xevyo-bas /home/sid/tuning/finetune/backend/output/xevyo-base-v1/merged_fp16_hf...
|
xevyo-base-v1
|
A love story of Della and Jim,
"The Gift of A love story of Della and Jim,
"The Gift of the Magi" is a short story by O. Henry about a young, poor couple, Della and Jim, who sacrifice their most prized possessions for Christmas gifts.
Characters and sacrifices: The story focuses on the married couple, Jim and Della Dillingham Young, who are in love but have very little money....
|
{"num_examples": 31, "bad_lines": {"num_examples": 31, "bad_lines": 0}...
|
/home/sid/tuning/finetune/backend/output/thsndkzt- /home/sid/tuning/finetune/backend/output/thsndkzt-8310/data/thsndkzt-8310.json...
|
{"train_runtime": 678.392, "train_samp {"train_runtime": 678.392, "train_samples_per_second": 2.359, "train_steps_per_second": 0.295, "total_flos": 6752424041693184.0, "train_loss": 0.22826169922947884, "epoch": 50.0, "step": 200}...
|
completed
|
1764310475
|
1764311549
|
NULL
|
/home/sid/tuning/finetune/backend/output/thsndkzt- /home/sid/tuning/finetune/backend/output/thsndkzt-8310/adapter...
|
False
|
Edit
Delete
|